17 April 2015c

PAUL M MAHAN MATTHEWS
p.matthews@imperial.ac.uk
PRIMARY APPOINTMENTS
July, 2014Edmond and Lily Safra Professor of Translational Neuroscience and Therapeutics, Division of Brain Sciences,
Department of Medicine, Imperial College London
Secured endowment for, and first holder of, new Chair associated with the Divisional Head and posts (Edmond and
Lily Safra Scholars) accompanying its foundation.
April, 2012Professor and Head, Division of Brain Sciences, Department of Medicine, Imperial College London
Leading a new integration of over 70 academics all clinical and basic neurosciences, neuropsychopharmacology,
neurology and mental health within a Division of 200 staff in the Faculty of Medicine with senior management
responsibilities across the three academic hospital sites of Imperial College, London. Additional responsibilities as
Deputy Director (2008- ) of the Wellcome Trust- GSK Translational Medicine Training Programme, Deputy Director(2011- ) of the BRC Institute for Translational Medicine and Therapeutics, Biomedical Research Centre (BRC) Theme
Lead for Neuroscience, co-Director of the Neurotechnology Network and the EPSRC Centre for Doctoral Training in
Neurology and Research Advisory Board for the Data Science Institute.
July, 2012- February 2014
Vice-President for Integrative Medicines Development, Neurosciences and Medicine Development Lead,
GlaxoSmithKline (joint appointment with Imperial College)
Leading late phase development programme. Senior advisor to the Head of Neurosciences and China R and D withspecific accountabilities for early phase neuroinflammatory disease strategy support to the Neuroinflammation DPU
Head and Leadership Team and for cross-unit imaging strategy. Leader in external engagement for multiple sclerosis
asset development. Responsibilities also include:
2010- Chair, Scinovations Committee, the major external science forum for GSK R and D, responsible for highprofile lectures and an annual GSK science sympsoium
2010- Experimental Medicine and Targets Advisory Board, which includes senior clinical scientists and special
advisors to the President, GSK Pharma R and D and has a remit to define, implement and monitor GSK
strategies for physician –scientist recruitment and new medicines concept development
2008- UK External Policy Committee, a senior committee with a remit to coordinate the GSK R and D responses andengagement with UK academia, external business and government
2005- Chair, Peer Review Forum, the (weekly) scientific review body for all early phase clinical protocols in Drug
Discovery
RECENT APPOINTMENTS BY THE SAME EMPLOYERS
Oct 2011- June, 2012
Vice-President for Imaging; Head, Global Imaging Unit (GIU), Center for Clinical Studies Excellence,
GlaxoSmithKline. I created and led GIU as an expert group with a remit to champion imaging experimental medicine
as a disruptive technology in clinical drug development. GIU coordinates investment and applications of imaging
across GSK R and D. GIU leads in concept and implementation of translational or clinical imaging strategies to drive
high-value assets with a focus on neurology, oncology and immune-inflammatory disorders. GIU partners with aninternational group of external imaging experts and centres of imaging research excellence. GIU also manages the£15 million investment in GSK access to London’s Imanova- the public-private partnership arising from successful
externalisation of the former GSK Clinical Imaging. Major accomplishments: creation of GIU and hiring of staff(including recruitment of my successor); development of external and internal operations network; initiation ofprogramme partnerships across therapeutic areas
Oct 2005- Oct 2011
Vice-President for Imaging; Head, GSK Clinical Imaging Centre (CIC), GlaxoSmithKline. Concept andimplementation of imaging experimental medicine for early clinical development or differentiation of GSK assets(particularly those in Neuroscience and Psychiatry development units); responsible for strategy and leadership for
imaging in the support of drug development and providing focused guidance of innovation in imaging across GSK
Pharma R and D; roles as Chief Executive Officer and Chief Scientific Officer of the £46 million clinical imaging centre
on the Hammersmith Hospital campus which employs a staff of 120 (70 GSK FTEs) with an approximately £20 million
annual budget (for external and internal spend). Major accomplishments: developed and implemented vision for the
CIC, the pharma industry’s first in-house clinical imaging unit; responsible for facilities completion and recruitment topeak staff of 70 FTE and 50 contingent workers, part-time staff and fellows/students from starting base of 11 FTE;
created structures and integrated imaging group with project teams across GSK R and D; established strategic,
productive alliances with UK universities and selected imaging companies and led in development of a new scientificpartnership model; delivery of 23 experimental medicine studies supporting assets (including albiglutide, lapatinib.

dustasteride, Alli, NiQuitin and multiple early assets) from across multiple GSK units (including the former2
Neurosciences CEDD, China R and D, Metabolic CEDD, Academic DPU, Rare Diseases Unit and the Oncology
Unit); development of unique training environment for imaging in experimental medicine; delivery of new sciencechampioning GSK commitment to “open science” with more than 200 peer-reviewed publications coming out of the
CIC between 2007-2011; lead transformation of the CIC into a novel UK public-private partnership (Imanova) to better
leverage external resources for innovation.
Oct 2006- March 2008
Vice-President for Imaging, Neurology and Genetics
Following hiring as Head of the Imaging Unit, I was asked to assume additional responsibilities to lead a strategic refocusing of GSK Medical Genetics involving additional management of 35 specialist staff and annual budget of over £6million/yr responsible for execution of population-based biomarker studies and whole genome studies of over 17,000
patients covering neuropsychiatry, metabolic, cardiovascular and respiratory disease. Major accomplishments:
reorganised group and transitioned successfully from data collection to strong partnerships for delivery of a successionof replicable whole genome association outcomes; added value and ensured opening of access to genetic datasets byengaging closely with the MRC, NIH and major academic centres; led in recruitment of new SVP head of Genetics andensured smooth transition of leadership.
Sept 2006- March 2013
Professor of Clinical Neurosciences, Centre for Neuroscience, Department of Medicine
Research post, also responsible for fostering integration of the GSK facility on the Hammersmith campus; teaching for
the MSc and PhD programmes in Translational Medicine
ADDITIONAL AND HONORARY APPOINTMENTS
2015Visiting Professor, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
2014Hon. Professor, School of Medical and Veterinary Sciences, Edinburgh University
2013Imperial College Healthcare Trust Biomedical Research Centre Neuroscience Theme Lead
2012Honorary Associate Professor, University of Maastricht
2011Visiting Associate Professor, Maastricht University
2010Visiting Professor, Department of Clinical Neurology, University of Oxford
2009Hon. Consultant Neurologist, Oxford Radcliffe Hospitals Trust, Oxford
2008Hon. Professor of University College London at the Institute of Neurology
2007Hon. Consultant Neurologist, Imperial College Academic Health Sciences Centre, Hammersmith
Hospital, London
1997Fellow by Special Election, St. Edmund Hall, University of Oxford
1996Adjunct Professor of Neurology, McGill University
PROFESSIONAL CERTIFICATIONS
2000
Fellow, Royal College of Physicians
1995
General Medical Council Registration No. 4250225
1993
Specialist Certificate (Neurology), Professional Corporation of Quebec
1992
Certificate in Neurology, American Board of Psychiatry and Neurology
1990
Specialist Certificate in Neurology, Royal College of Physicians and Surgeons, Canada (FRCPC)1987
Diplomate, National Board of Medical Examiners
EDUCATION AND PROFESSIONAL EXPERIENCE
Education
1974-78
BA (Hons), Honour School of Natural Sciences (Chemistry), St. Edmund Hall, University of Oxford
1978-82
D. Phil., Dept. of Biochemistry, University of Oxford
1983-86
M.D., Stanford University School of Medicine
Postgraduate Training
Research
1982-83
Postdoctoral Fellow, Dept. of Biochemistry and Clinical Magnetic Resonance Laboratory, Radcliffe
Infirmary, University of Oxford
1983-84
Postdoctoral Fellow, Dept. of Pharmacology, Stanford University
1989-90
Clinical Research Fellow (Neurogenetics), Montreal Neurological Institute, McGill University
1990-93
MRC (Canada) Clinician-Scientist, Genetics Laboratory, Department of Biochemistry, University of
OxfordMedicine
1986-87
1987-90
1991-93

Intern (Medicine), Stanford University Medical Centre
Resident in Neurology and Chief Resident (1989), Department of Neurology and Neurosurgery, McGill
University, Montreal, Canada
Hon. Senior Registrar and Acting Clinical Lecturer, Department of Clinical Neurology, University of Oxford

Previous Academic and Hospital Appointments by other employers
32004-2005
Head, Department of Clinical Neurology, University of Oxford
1998-2005
Professor of Clinical Neurology, University of Oxford
1996-2006
Hon. Consultant in Neurology, Oxford Radcliffe Trust
1995-2005
Director, Oxford Centre for Functional Magnetic Imaging of the Brain
1995-98
Reader in Neurology, University of Oxford
1993-96
Assistant Professor of Neurology and Neurosurgery and Human Genetics, McGill University, Montreal,
CanadaStaff Neurologist, Montreal Neurological Hospital
Attending Neurologist, Montreal Children’s Hospital
Attending Neurologist, Jewish Rehabilitation Hospital
CURRENT AND RECENT EXTERNAL COMMITTEE SERVICEUK Research Council and related
2014Director, Translational Research Centre-Dementia (TRC-D), Imperial College London
2013Steering and Executive Committee, Dementia Platforms UK and Chair, Dementia Platforms UK Imaging
Network
2012
Japan Science and Technology Research Council-MRC Committee for Bilateral Science
2012
MRC Advanced Translational Training Panel (Chair, Imaging Sub-Panel)
2011
EPSRC Medical Imaging Technologies Review Working Group
2011Research Excellence Framework (REF) Sub-Panel 4: Neurosciences
2011
BBSRC, MRC and Wellcome Trust 'Post-Weatherall' 10 year Review Committee on Non-humanPrimates Research2010
Research Excellence Framework (REF) Impact Pilot Panel
2009UK Biobank Imaging Enhancements Working Group
2009-11MRC Industrial Collaborative Training and Career Panel
2008-10
MRC Translational Medicine Group
2008MRC NMHB SPOG PET Strategy Group2007
MRC NMHB SPOG Addiction Strategy Steering Group
2007-09
MRC Toxicology Unit National Training Scheme Steering Committee
2007-09
Co-chair, MRC-GSK Complex Genetics Initiative
2006-08
MRC Neurosciences and Mental Health Strategic Portfolio Oversight Group (SPOG)2006
MRC Experimental Medicine Panel
2004-10MRC Neurosciences and Mental Health Board
Charities
20142012201120112011
2010
2009-12
2009-10
20092006-08
International
2014-152014201420142014
2013201320132013
2013
20112011

Chair, Brain Board of Management
Working Party on Genomics, Health Records, Database Linkage and Privacy, Nuffield Council on
Bioethics
Chair, Imaging Enhancements Working Group, UK Biobank
UK Biobank Steering Group
NC3R Working Group on Metrics
British Neurosciences Association Scientific Advisory GroupMS Society of Great Britain/Northern Ireland, Research Strategy Group
Association of British Pharmaceutical Industries Working Group on Stratified Medicines
Scientific Advisory Panel, Oxford Parkinson’s Disease GroupMS Society of Great Britain/Northern Ireland, Strategy Advisory Board

Chair, Academy of Finland Scientific Review Panel
Brain Canada Multi-Investigator Research Initiative Selection Committee
American Institute of Biological Sciences Oversight Panel for the New York Consortia to Accelerate
Applications of Stem Cells
Scientific Advisory Board, International Conference on Brain Engineering and Neuro-computing (ICBrainEngiNe)
Ad hoc member, NIH NINDS Board of Scientific Counselors
International Steering Group for the Literature and Science Programme
Hon. President (2014- ) (Hon. Vice President [2013-14]), London Healthcare Forum, Korean HealthIndustry Development Initiative
Steering Committee, Multiple Sclerosis Outcomes Assessment Committee, Critical Path Institute, USA(Regulatory Task Force, Feb 2014-)
External Review Panel, Donders Institute, June 2014
Chair, NC3R Imaging Technology Development Panel and Symposium, May 2013
International Steering Committee, Clusters of Excellence in Neurodegeneration (COEN) Research
Network
Chair, Canadian Institutes of Health Sciences, National Imaging Consortia Competition

20102009
2004-

International Jury, Wiener Wissenschafter-, Forschungs- and Technologies- Fond (Chair, 2014)
Canadian Institutes of Health Sciences, special working group for national review of imaging strategy
Member, European Dana Alliance

4

AWARDS NIHR Senior Investigator (2015)
 Fellow of the Academy of Medical Sciences (2014)
 Hon. Officer of the Order of the British Empire (2008) awarded for services to neuroscience Elected Membership, Association of Physicians (2010)
 MRC Clinical Research Professor (2000-08) (full salary and research support competitively awarded in national
competition for excellence in research, transitioning to honorary appointment with research funding after taking up
GSK position [2005-08])
 MRC Clinical Research Reader (1995-2000) (full salary and research support, competitively awarded in national
competition for excellence in research) Feindel Neuroimaging Lectureship (2009), McGill University
 Elected and renewed serially as a Fellow by Special Election, St. Edmund Hall, University of Oxford (1997present)
 MRC (Canada) Clinician-Scientist Award (1990), competitive 5 year full salary and research support award forclinician-scientist career development
 Penfield-McNaughton Award (1990), awarded annually by the Montreal Neurological Institute to most outstanding
leaving specialist trainees
 Foulkes Foundation Clinician-Scientist Training Award (1982), nationally competitive full tuition award for nonclinical scientist to train in medicine
 National Science Foundation Pre-doctoral Fellowship (1979), research support and tuition costs for DPhil in
OxfordCURRENT AND MAJOR EXTERNAL RESEARCH AND TRAINING GRANTS
Principal Investigatorstst NIHR Senior Investigator award. £450,000 (£375,000 to ICH Trust) (1 April 2015- 31 March 2020).
 MRC Capital Research Infrastructure Bid, UKDP: Integrated DEmentiA research environment (IDEA). Imperial
College PI and UKDP Imaging Network Lead responsible for national imaging component (£20 million, on
behalf of 6 universities [Imperial College component, £5.6 million) of the £40 million total bid, Dr. J. Gallacher,PI).
 MS Society of Great Britain and Northern Ireland Innovation Grant. Assessing myelostructure as an index ofgrey matter disease progression in multiple sclerosis using high-resolution, 1 dimensional MRI. PI, £40,000 (1Oct 2014- 31 Sept 2015).
 International Progressive MS Alliance Pilot Grant. Novel enabling infrastructure for outcomes monitoring:
dynamic remote performance capture to assess disability in progressive multiple sclerosis, €74,995 (1 Aug
2014-31 July 2015, PA 0103)
 Imperial College Healthcare Trust NIHR Biomedical Research Centre, Towards rapid, expression-based
pharmacodynamic medicines stratification, PI, £200,000 (1 April 2014-31 March 2016)
 Biogen IDEC, The OPTIMISE Portal: a flexible, eTRIKS-based platform for MS data capture and sharing, PI,€725,000 (1 Sept 2014-31 Aug 2017, subject to contract)
 MRC Collaborative Training Programme for NeuroPET (PI, £599,998) (2010-2013)
 MRC Equipment Grant, Functional Imaging of the Heart and Brain (PI, £134,000) (2004)
 MRC, Linking structure and function in the normal and in the diseased human brain (PI, £1,050,000) (20032008)
 MRC, Towards quantitative fMRI for serial studies of the normal and diseased brain (PI, £585,677) (20032008)
 MRC, Mechanisms of long-term recovery with subcortical ischaemic disease (PI, £1,179,802 plus funding for
MRC Clinical Research Professorship) (2002-2007)
 MRC, FMRIB Core facility extension (PI, £420,743) (2002-2003)
 MRC, Functional imaging of the heart and brain (Cooperative Group Grant) (PI, £351,992) (2000-2004)
Co-Principal Investigator UK Dementias Platform Capital Research Infrastructure (co-PI for £20 million multi-institution imaging
component [£5.6 million to Imperial College] with UKDP Lead as PI), MRC Capital Award (Oct 2014-March2016)
 UK Biobank Imaging Enhancement Pilot (co-I [with Biobank CEO as PI] and Chair, Imaging Working Group),
Pilot phase, £10 M with trigger for additional £26M), MRC/Wellcome Strategic Award (2013- 2015 pilot withtrigger for 2015-2019) FP7, Neurophysics- Methods in Neuroimaging (co-PI and UK Lead, €659,602) (2010-14)
 Wellcome Trust-GSK Training Programme in Translational Medicine (co-PI and Deputy Director, £5,500,000)(2009-2017)



MRC, Anatomical Connectivity in Adolescent-onset Schizophrenia (co-PI, £168,000) (2005-2007)
BBSRC, The neural architecture of primate visuospatial attention (co-PI, £162,930) (2004-2007)5

Co-investigator Joint Programme- Neurodegenerative Disease, Realising the potential of cohort studies to determine thevascular contribution to neurodegeneration, Working Group Infrastructure Funding, co-I (Prof. J. Wardlaw, PI)€47,416 (1 Oct 2014- 31 March 2015)
 MRC, MRC Dementias Platform, co-I, £4.5 M (1 April 2014-31 March 2019) MR/L015382/1
 MRC, MICA. Assessing tau levels after traumatic brain injury (TBI) using [18F]T807 positron emission
tomography (PET), co-I, £550,000, (1 June 2014- 28 May 2016, MR/L022141/1)
 EPSRC Centre for Doctoral Training in Neurotechnology (Co-PI, £10.2m) (2014-2019, EP/L016737/1)
 MRC Project Grant, Identification of genetic variants underlying Type 2 diabetes in UK Indian-Asians (co-PI,£600,006) (2007-10)
RESEARCH TRAINEES
Doctoral students
1992-1996
Masha LeGris, DPhil
1994-1997
Jules Griffin, DPhil
1996-1999
Sarah Pendlebury, DPhil
1997-2000
Martin Lee, DPhil
1997-2000
Niko Evangelou, DPhil
1998-2001
Hasini Reddy, DPhil
1998-2001
Heidi Johansen-Berg, DPhil
2000-2003
Allyson Parry, DPhil
2000-2003
Vivian Austin, DPhil
2000-2003
Donna Lloyd, DPhil
2001-2004
Afua Basoah, DPhil
2001-2004
Charvy Narain, DPhil
2001-2004
Anna Floyer, DPhil
2000-2004
Ron Heal, DPhil
2001-2005
Sheela Saini, DPhil
2001-2005
Teddy Tjandra, D Phil
2001-2004
Marko Bogdanovic, MD
2002-2005
Marilena de Luca, D Phil
2002-2005
Natalie Voets, D Phil
2002-2005
Yasir Obu-Omar, DPhil
2002-2006
Stephanie Manson, DPhil
2003-2006
Sean David, D Phil
2003-2006
Helen Jamison, DPhi
2003-2006
Christine Wegner, DPhil
2003-2006
Sarah Cader, DPhil
2003-2006
Ian Pomeroy, DPhil
2004-2007
Charlotte Stagg, DPhil
2005-2009
Rose Bosnell, DPhil
2008-2011
David Owen, PhD
2008-2012
Paul Shotbolt PhD
2010Evangelos Russo (PhD expected 2014)
2010Rhamzi Kamzis (PhD expected 2014)
2010Alessandro Colassanti (PhD expected 2014)
2011Jaime Vera (PhD expected 2015)
2013Gourab Datta (PhD expected 2017)
2014Arie Gafson (PhD expected 2017/18)
MSc research students
1998
Elizabeth Tunbridge
1998
Josephine Raley
1998
Heidi Johansen-Berg
2000
Anna Floyer
2003
Catherine Whitwood
2003
Cherif Sayhoun
2003
Emma Sillery
2003
Kate Sheehan
2004
Siri Braathen
2004
Tobias Overath
2004
Tim Senior
2004
Sarah Carrington

PUBLIC ENGAGEMENT WITH SCIENCE

6

Committed communicator of science with active participation in Dana Alliance public events (e.g., 2009 British Association
for the Advancement of Science, 2013 An Evening with Andrew Marr [lecture on Art and Neuroscience], Charing Cross
Hospital, 2012 Cold Spring Harbor Workshop on Literature and the Brain and Science and Art Symposium, Wolfson
College, Oxford, 2011 Stay Sharp, conference speaker 2013 ICLA Symposium Lecture), GSK and Royal Institution press(appearances on BBC radio and television [including Newsnight, 27 July, 2011], press briefings on GSK strategies) andpolitical briefings (hosting high level parliamentary, European parliamentary and civil service visitors to CIC over last few
years) and interviews in review articles across lay and scientific press including Nature, Nature Reviews Neuroscience,
Science and on-line (see e.g., “Meet the Boss” on YouTube). Selected as a lead for presentation of the Nuffield Council
on Bioethics “Big Data” Report, 2015.
PROFESSIONAL SOCIETIESRoyal College of Medicine, Association of British Neurologists, American Academy of Neurology, Society for
Neuroscience, International Society for Magnetic Resonance in Medicine, British Neuroscience Association
CLUBAthenaeum
RECENT EXTERNAL SPEAKING ENGAGEMENTS
2015
Pervasive Actigraphy and EEG Monitoring for Multiple Sclerosis
Sensors in Medicine 2015, London
March 2015
Global Collaboration and Initiatives
2015 WKMO European Forum & London Health Forum, London
March 2015
Big data for healthcare research: UK Biobank and Dementias Platforms UK
UK-Korea Future Health Forum, Seoul, Korea
March 2015
Molecular imaging of microglia in multiple sclerosis and the intriguing biology of the 18 kD mitochondrial translocator
protein (TSPO)TMII Seminar Series, New York, USA
March 2015
Accessing New Tools for Clinically-focused research in Neurology: patient monitoring sensors and "Big Data"
resources
Imperial College London Division of Brain Sciences’ lecture series, London
February 2015
2014
Brain health: it takes more than pills and potions
Inaugural lecture of Professor Paul M Matthews, Edmond and Lily Safra Chair in Translational Neuroscience andTherapeutics
November 2014
Neuroscience “guerrilla warfare” in the fight against dementia
Neuroscience & Mental Health Research Institute seminar series, Cardiff, UK
November 2014
PET imaging of inflammation and myelin: new opportunities and challenges
Neurimmunology and Clinical Multiple Sclerosis Research) series, Zurich
October 2014
Smartphones for Mental HealthImperial College-Huawei Workshop on Big Data, London
September 2014
Personalized medicine: Can we tailor individual therapy for patients?
World Congress on NeuroTherapeutics Dilemmas
Basel, Switzerland
September 2014

Translational neuroimaging: has the "cutting edge" had clinical impact?
William Moore Memorial Lecture, British Chapter ISMRM, Edinburgh
September 2014
Medical need, large group studies and emerging opportunities for advances in MRI and PET imaging
Institute of Physics Plenary Lecture at the Institute of Physics and Engineering in Medicine Annual Conference,
Glasgow
September 2014
Grand challenges mean great opportunities: emerging science to transform future healthcare
Invited Lecture, Zheijing University, Hangzhou, China
July 2014
Ethical considerations for research imaging: maintaining privacy, autonomy and the management of unexpected
finding
Invited Lecture, Organisation for Human Brain Mapping Annual Meeting, Hamburg, Germany
June 2014
Building on a translational academic hospital ecosystem to address the challenges of dementia
Korea-UK Research Driven Hospitals International Forum, Seoul, Korea
June 2014
UK Biobank - Design and Outlook
Invited Symposium Lecture, German Radiology Congress, Hamburg, Germany
May 2014
The Physician's Expectations for Human UHF
Plenary Lecture, International Society for Magnetic Resonance Annual Meeting
Milan, Italy
May 2014
Connectivity Studies in Large Populations
Invited Educational Lecture, Teaching Session, International Society for Magnetic Resonance Annual Meeting
Milan, Italy (Outstanding Teacher Award Winner)
May 2014
Standardization of Data for Clinical Care and Clinical Trials
Invited Lecture, Multiple Sclerosis Outcomes Assessment Consortium/FDA Workshop, Bethesda, USA
April 2014
Strategies for patient stratification
Invited Lecture, Multiple Sclerosis Disease Workshop: “Towards a No Evidence of Disease Paradigm”, London
March 2014
Brain Plasticity and the Conundrum of Disability Progression in Multiple Sclerosis
Invited Lecture, Canadian MS Society National Neuroinflammation Symposium, Toronto, Canada
February 2014
Imperial Brain Sciences and a College commitment to Public-Private Partnerships for Therapeutics Development
MRC Clinical Sciences Centre Innovation Workshop, London
February 2014
2013
Molecular imaging in new medicine development
International Symposium on Drug Development Imaging Technology, Hanyang University, Seoul, Korea
December 2013
Clinical imaging for new medicine development
Samsung Medical Centre, Seoul, Korea
December 2013
Innovation challenges for clinical imaging in new drug development
Gil Medical Centre, Seoul, Korea
December 2013
Beyond mere biomarkers: taking on the challenge of stratified medicine
Distinguished Lecture, MS Masterclass, Bristol

7

November 2013

8

The Art of the Brain and understanding the Brain through Art
Invited speaker, An Evening with Andrew Marr in Aid of the Stroke Unit, Charing Cross Hospital
October 2013
So you want to develop a drug?
Invited speaker, MRC Seminar Series
October 2013
Imaging in UK Biobank
Invited speaker, Annual Royal College of Radiologists/Wellcome Trust Research day, London
October 2013
UK Biobank: the imaging enhancement and promise as a platform for dementia research
Keynote Speaker, 2nd International Conference on the Standard Construction of Beijing Biobank of ClinicalResources, Beijing
September 2013
The UK-Korea Academic Health Science Alliance Initiative
Convenor’s Introduction, London Health Forum
September 2013
Raising the Bar in MS
Invited Speaker, AIMS regional meeting, London,
September 2013
Dementia and the fragmentation of the self (read by Dr. Jan Winkowski)
Invited Symposium Speaker and Workshop Co-convenor, International Comparative Literature Annual Conference,
Paris
July 2013
Neurotechnology as a therapeutic modality
Invited Speaker, Tsinghua University, Beijing, China
July 2013
Entering a new era of large scale, open imaging resources
Invited Lecture, Imaging Neurodegeneration and Neuroprotection in MS Symposium, London
July 2013
Major problems in MS
Invited Speaker, ISMRM Educational Symposium: Multiple Sclerosis as a Whole-Brain Disease, UCL, London
June 2013
Imaging technology development for the 3Rs
Invited Chair, NC3Rs/ESP KTN Workshop, London
June 2013
Opportunities for International Collaborative Healthcare Science
Invited Address to Delegates, 2013 London Health Forum, Korean Healthcare IDI, London
May 2013
Emerging evidence on brain atrophy as a measure of disease progression and treatment effectInvited Symposium Lecture, Association of British Neurologists, Glasgow,
May 2013
OPTIMISE: a programme for stratified medicine in MS
Invited Speaker, One Mind for Research Annual Meeting, Johns Hopkins University, Baltimore, Maryland, May 2013
Neurodegeneration and inflammation
Invited Lecture, From Science to Therapeutics: The Best Way Forward: a Gladstone Institute-DZNE Workshop, UCSF,
USA
April 2013
Connectivity Studies in Large Populations: Towards Defining Disease Mechanisms & Risk
Invited Lecture, ISMRM Annual Meeting Educational Course, Salt Lake City, USA
April 2013

OPTIMISE: a UK Consortium for Stratified Medicine
Invited Lecture, UK MS Debating Society
March 2013

9

A national effort for translational neuroscience and imaging, rare disease medicine development
Wellcome Trust, London
February 2013
Industry-academic partnerships for rare disease medicine development
Invited Lecture, UCL - Great Ormond Street Hospital Rare Diseases Workshop
February 2013
2012
Functional MRI: overview and potential utility for assessing stem cell therapy in Parkinson’s Disease
Invited Lecture, FP7 NeuroStem Initiative Consortium, London
September 2012
fMRI Methods for Multiple Sclerosis
Invited Lecture, European MAGNIMS Consortium, London
June 2012
UK Imaging Science: an overview
Invited Workshop, MRC-Japan Science and Technology Collaborative Workshop, Tokyo
June 2012
PET imaging of microglial activation with PET
National Institute of Neurological Disease, Tokyo
June 2012
Microglial imaging in multiple sclerosis
Distinguished Professorial Lecture Series, Dept. Of Radiology, Case Western Reserve University
May 2012
Recovery after brain injury and the integrity of white matter
Cleveland Clinic Foundation “Myelin Madness” Lecture Series
May 2012
Alzheimer’s Disease and the fragmentation of the self
Neuroscience and Literature Symposium, Banbury Centre, Cold Spring Harbor, USA
April 2012
Biomarkers of therapeutic response
American Academy of Neurology Annual Teaching Course, New Orleans, LA USA
April 2012
Shakespeare’s neurology
UK Annual MS Debating Society Keynote Lecture
Basingstoke, UK
March 2012
Healthy brain aging
U3A Annual Conference, East Grinstead, UK
March 2012
Imaging brain microglia activated with multiple sclerosis: understanding genetic variation underlying PET radioligand
affinity
Department of Radiology, Yale University
Feb 2012
Japan-UK collaborative science in multimodal brain imaging (Chair’s opening remarks)
UK-Japan Multimodal Brain Imaging Symposium, Kavli Centre, UK
Feb 2012
2011
Genetics in drug discovery and development
Weatherall Institute of Molecular Medicine Seminar Progroamme, University of Oxford
November, 2011

10
Imaging the dynamic neuropathology of multiple sclerosis
Seminar Series Lecture, Medical Sciences Division, University of Aberdeen
October 2011
Casting light on the dark side: new opportunities with a changing pharma model
Grand Rounds, Nuffield Dept of Clinical Neurosciences, University of Oxford
October 2011
Functional reorganisation and rehabilitation
Invited Lecture, European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Amsterdam
October 2011
Achieving effective translation
Invited lecture, Next Generation Brain Imaging Technologies, Wellcome Trust
October 2011
Imaging activated microglia using PETBrigham and Women’s Hospital, Harvard University, Boston USA
September 2011
How the physical sciences created clinical imaging and transformed modern medicine
Physical Sciences Alumni Weekend Plenary Lecture, St Edmund Hall, University of Oxford
September 2011
Extending the phenotype in association studies through imaging genomics
BHF Centre of Excellence Annual Symposium Lecture, Nuffield Department of Medicine, University of Oxford
September, 2011
Lessons from brain plasticity in multiple sclerosis
Invited Lecture, Consortium of MS Centers Annual Meeting, Montreal
June 2011
Co-chair introduction & overview: magnetic resonance spectroscopy- a re-emerging tool for neuroscience.
Morning Symposium, International Society for Human Brain Mapping Annual Meeting, Quebec City
June 2011
Advanced imaging for experimental medicine in oncology: opportunities and challenges
Invited workshop: Exploring Canada-UK-US Synergies for Medical Imaging, Canadian High Commission, London
June 2011
Biomarkers and the design of clinical trials for neuroscience drug development
Masterclass in CNS therapeutics, SMI Group, London
April 2011
Chair’s introduction and overview – Gut & Brain Symposium
British Neuroscience Association, Harrogate
April 2011
Staying sharp! The neuroscience of healthy aging
University of the Fourth Age Annual Conference, The Royal Society, London
April 2011
The challenge of imaging neurodegeneration in Parkinson’s disease
Oxford Parkinson’s Disease Consortium Seminar, Dept of Physiology, Anatomy & Genetics, University of Oxford
March 2011
fMRI and translational medicine: an historical view
Wellcome Trust Training Programme Seminar Series, Dept of Investigative Medicine, Imperial College, London
March 2011
Brain imaging for population-based epidemiology
UK Biobank Launch Meeting, Wellcome Trust, London
March 2011

Industry, academia and the future of experimental medicine
11
University College, London, Comprehensive Biomedical Research Centre Conference. Mermaid ConferenceCentre, London
March 2011
Advances in Multiple Sclerosis
Royal College of Physicians Advanced Medicine Course, London
February 2011
Imaging genomics: from molecule to systems
Centre for Neurodegenerative Disease, VA Medical Centre, University of California, San Francisco
February 20112010
Imaging biomarkers for neurodegeneration
British Council Invited Lecture, UK-Malaysia Symposium on Neurodegeneration, Monash University, Kuala Lumpur
December 2010
Therapeutics development: changing the paradigm
British Pharmacological Society workshop Invited lecture, QEII Conference Centre, London
December 2010
Biomarkers for neurodegeneration
British Council Invited Lecture and workshop participant, UK-Singapore ‘Partners in Science’ International Symposium,
A* Biopolis & Duke/ National University of Singapore
November 2010
Imaging brain remodelling in multiple sclerosis: current research and future developments
Magnetic Imaging in MS (MAGNIMS) Invited Speaker, Warwick Castle
November 2010
Multimodal neuroimaging: from molecules to systems
Invited Lecture, Dept of Neurology, University of California, San Francisco
November 2010
An introduction to molecular imaging and its use for drug development in neurology
Invited lecture, Autumn Workshop on Molecular & Functional Imaging in Clinical Practice, British Institute ofRadiologists, London
October 2010
Brain imaging for understanding the molecular bases of cognition
Killem Lecture, Montreal Neurological Institute, Montreal
October 2010
Pharmacology & fMRI: principles and applications
Teaching workshop lecture: Brain imaging and its applications, EU Framework Training Programme, Great Malvern
July 2010
New drugs for the developing world
UniQ Summer School Lecture and Workshop, University of Oxford
July 2010
Imaging genetics and multimodal approaches
Summer fMRI Course Invited Lecture, Imaging Center, University of California, Los Angeles
July 2010
MRI in MS – How should it be used?
MS Masterclass, Marriott Park Royal Hotel, Bristol
June 2010
Brain Imaging for UK Biobank
UK Biobank Enhancement Meeting, Wellcome Trust, London
May 2010
Multimodal imaging for drug development
Invited Lecture and UK Lead, Japan-UK Science Workshop, British Embassy, Tokyo
January 2010

12
2009
st
Translation of new technologies towards the clinic, drug discovery and development in the 21 century
FRAME symposium, The Royal Society, London
November 2009
Imaging for translational neuroscience drug development
Keynote speaker, Medical Imaging Workshop, Canadian Institutes of Health Research, Vancouver
October 2009
Functional and molecular imaging for translational neuroscience
Plenary Lecture, Neuroscience Ireland Annual Meeting, Dublin
September 2009
Imaging for translational medicine
Invited Speaker, Institute for Translational Medicine & Therapeutics 2009 International Symposium ‘Global Approaches
to Translational Research’, University of Pennsylvania
May 2009
MRI in drug development
Invited Sunrise Course, International Society for Magnetic Resonance in Medicine, Stockholm
April 2009
The plastic brain: skill learning and motor recovery after brain injury
Professorial inaugural lecture, Imperial College, London
January 2009
Imaging plasticity in the human brain
Feindel Lecture, Montreal Neurological Institute, Montreal
January 2009
Using MRI to study MS: understanding plasticity
Invited Keystone Symposium speaker, Santa Fe, New Mexico
January 2009
PUBLICATIONSOver 325 peer-reviewed papers published and in press; co-authored 5 books published or in press (including a 2004 IPPY
Award Winner for Best Books of the Year) and over 50 additional chapters, letters and reviews; Google Scholar h-index
106 (76 since 2009); i10 index 293 (245 since 2009).
Peer Reviewed Papers
2015
Matthews PM, Datta G. 2015. Positron-emission tomography molecular imaging of glia and myelin in drug discovery
for multiple sclerosis. Expert Opin Drug Discov. 5:1-14. [Epub ahead of print]
Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B,
Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. 2015. UK Biobank: An Open
Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLoS
Med. 12(3):e1001779
Comninos AN, Anastasovska J, Sahuri-Arisoylu M, Li X, Li S, Hu M, Jayasena CN, Ghatei MA, Bloom SR, Matthews
PM, O'Byrne KT, Bell JD, Dhillo WS. 2015. Kisspeptin signaling in the amygdala modulates reproductive hormone
secretion. Brain struct funct. [Epub ahead of print]
Jacobs HI, Wiese S, van de Ven V, Gronenschild EH, Verhey FR, Matthews PM. 2015. Relevance ofparahippocampal-locus coeruleus connectivity to memory in early dementia. Neurobiol aging. 36(2):618-26
2014
Douaud G, Groves AR, Tamnes CK, Westlye LT, Duff EP, Engvig A, Walhovd KB, James A, Gass A, Monsch AU,
Matthews PM, Fjell AM, Smith SM, Johansen-Berg H. 2015. A common brain network links development, aging, andvulnerability to disease. Proc Natl Acad Sci U.S.A. 111(49):17648-53
Suri S, Mackay CE, Kelly ME, Germuska M, Tunbridge EM, Frisoni GB, Matthews PM, Ebmeier KP, Bulte DP, Filippini
N. 2014. Reduced cerebrovascular reactivity in young adults carrying the APOE ε4 allele. Alzheimers Dement. pii:
S1552-5260(14)02467-4

Khamis RY, Woollard KJ, Hyde GD, Boyle JJ, Bicknell C, Hara T, Mauskapf A, Granger DW, Johnson JL,13Ntziachristos V, Matthews PM, Jaffer FA, Haskard D. 2014. C Development of Whole Body and Intravascular Nearinfrared Optical Molecular Imaging of Markers of Plaque Vulnerablity in Atherosclerosis. Heart.100 Suppl 3:A128
Colasanti A, Guo Q, Muhlert N, Giannetti P, Onega M, Newbould RD, Ciccarelli O, Rison S, Thomas C, Nicholas R,
Muraro PA, Malik O, Owen DR, Piccini P, Gunn RN, Rabiner EA, Matthews PM. 2014. In Vivo Assessment of Brain
White Matter Inflammation in Multiple Sclerosis with 18F-PBR111 PET. J Nucl Med. 55(7):1112-1118
Owen DR, Guo Q, Kalk NJ, Colasanti A, Kalogiannopoulou D, Dimber R, Lewis YL, Libri V, Barletta J, RamadaMagalhaes J, Kamalakaran A, Nutt DJ, Passchier J, Matthews PM, Gunn RN, Rabiner EA. 2014. Determination of[(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study. J Cereb Blood Flow Metab. 34(6):989-94
Linortner P, Jehna M, Johansen-Berg H, Matthews PM, Schmidt R, Fazekas F, Enzinger C. 2014. Aging associatedchanges in the motor control of ankle movements in the brain. Neurobiol Aging. [Epub ahead of print]
Matthews PM. 2014. The virtues of adaptability. Mult Scler. 20(4):394-6
Newbould RD, Nicholas R, Thomas CL, Quest R, Lee JS, Honeyfield L, Colasanti A, Malik O, Mattoscio M, Matthews
PM, Sormani MP, Waldman AD, Muraro PA. 2014. Age independently affects myelin integrity as detected bymagnetization transfer magnetic resonance imaging in multiple sclerosis. Neuroimage Clin. 4:641-8
Matthews PM, Geraghty OC. 2014. Understanding the pharmacology of stroke and multiple sclerosis throughimaging. Curr Opin Pharmacol. 14C:34-41
Matthews PM, Edison P, Geraghty OC, Johnson MR. 2014. The emerging agenda of stratified medicine in neurology.
Nat Rev Neurol. 10(1):15-26
2013
Wu C, Zhu J, Baeslack J, Zaremba A, Hecker J, Kraso J, Matthews PM, Miller RH, Wang Y. 2013. Longitudinal
Positron Emission Tomography Imaging for Monitoring Myelin Repair in the Spinal Cord. Ann Neurol. 74(5):688-98
Zarei M, Beckmann CF, Binnewijzend MAA, Schoonheim MM, Oghabian MA, Sanz-Arigita EJ, Scheltens P, Matthews
PM, Barkhof F. 2013. Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's
disease. Neuroimage. 66C:28-35
Guo Q, Colasanti A, Owen DR, Onega M, Kamalakaran A, Bennacef I, Matthews PM, Rabiner EA, Turkheimer FE,
Gunn RN. 2013. Quantification of the Specific Translocator Protein Signal of F-18-PBR111 in Healthy Humans: A
Genetic Polymorphism Effect on In Vivo Binding. J Nucl Med. 54(11):1915-23
Kandel ER, Markram H, Matthews PM, Yuste R, Koch C. 2013. Neuroscience thinks big (and collaboratively), Nat Rev
Neurosci. 14(9):659-64
Colasanti A, Owen DR, Grozeva D, Rabiner EA, Matthews PM, Craddock N, Young AH. 2013. Bipolar Disorder isassociated with the rs6971 polymorphism in the gene encoding 18kDa Translocator Protein (TSPO).
Psychoneuroendocrinology. 38(11):2826-9
Matthews PM, Matthews EA. 2013. Expanding perception through the disordered brain. The Lancet. 381(9871):98586
Newbould RD, Miller SR, Upadhyay N, Rao AW, Swann P, Gold GE, Strachan RK, Matthews PM, Taylor PC, Brown
AP. 2013. T1-weighted sodium MRI of the articulator cartilage in osteoarthritis: a cross sectional and longitudinal study.
PLoS One. 8(8):e73067
Gourraud PA, Sdika M, Khankhanian P, Henry RG, Beheshtian A, Matthews PM, Hauser SL, Oksenberg JR, Pelletier
D, Baranzini SE. 2013. A genome-wide asssociation study of brain lesion distribution in multiple sclerosis. Brain.
136(4):1012-24
Douaud G, Menke RA, Gass A, Monsch AU, Rao A, Whitcher B, Zamboni G, Matthews PM, Sollberger M, Smith S.
2013. Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild
cognitive impairment to Alzheimer’s disease. J Neurosci. 33(5):2147-55
Inkster B, Strijbis EM, Vounou M, Kappos L, Radue EW, Matthews PM, Uitdehaag BM, Barkhof F, Polman CH,
Montana G, Geurts JJ. 2013. Histone deacetylase gene variants predict brain volume changes in multiple sclerosis.
Neurobiol Aging. 34(1):238-47

Strijbis EM, Inkster B, Vounou M, Naegelin Y, Kappos L, Radue EW, Matthews PM, Uitdehaag BM, Barkhof F,14
Polman CH, Montana G, Geurts JJ. 2013. Glutamate gene polymorphisms predict brain volumes in multiple
sclerosis. Mult Scler. 19(3):281-8
Matthews PM, Filippini N, Douaud G. 2013. Brain structural and functional connectivity and the progression ofneuropathology in Alzheimer’s disease. J Alzheimers Dis. 33 Suppl 1:S163-72
Petersen SE, Matthews PM, Bamberg F, Bluemke DA, Francis JM, Friedrich MG, Leeson P, Nagel E, Plein S,
Rademakers FE, Young AA, Garratt S, Peakman T, Sellors J, Collins R, Neubauer S. 2013. Imaging in population
science: cardiovascular magnetic resonance in 100,000 participants of UK Biobank-rationale, challenges andapproaches. J Cardiovasc Magn Reson. 15:46
2012
Newbould RD, Miller SR, Tielbeek JA, Toms LD, Rao AW, Gold GE, Strachan RK, Taylor PC, Matthews PM, Brown
AP. 2012. Reproducibility of sodium MRI measures of articular cartilage of the knee in osteoarthritis. Osteoarthritis
Cartilage. 20(1):29-35
Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, Rhodes C, Pulford DJ, Bennacef I, Parker CA, Stjean
PL, Cardon LR, Mooser VE, Matthews PM, Rabiner EA, Rubio JP. 2012. An 18-kDa translocator protein (TSPO)
polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab.
32(1):1-5
Matthews PM, Rabiner EA, Passchier J, Gunn RN. 2012. Positron emission tomography molecular imaging for drug
development. Br J Clin Pharmacol. 73(2):175-86
Libri V, Brown AP, Gambarota G, Haddad J, Shields GS, Dawes H, Pinato DJ, Hoffman E, Elliot PJ, Vlasuk GP,
Jacobson E, Wilkins MR, Matthews PM. 2012. A pilot randomized, placebo controlled, double blind Phase I trial of thenovel SIRT1 activator SRT2104 in elderly volunteers. PLoS One. 7(12):e51395
Zarei M, Beckmann CF, Binnewijzend MA, Schoonheim MM, Oghabian MA, Sanz-Arigita EJ, Scheltens P, Matthews
PM, Barkhof F. 2012. Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer’s
disease. Neuroimage. 66C:28-35
Tomassini V, Matthews PM, Thompson AJ, Fuglø D, Geurts JJ, Johansen-Berg H, Jones DK, Rocca MA, Wise RG,
Barkhof F, Palace J. 2012. Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol. 8:365-46
Politis M, Giannetti P, Su P, Turkheimer F, Keihaninejad S, Wu K, Waldman A, Malik O, Matthews PM, Reynolds R,
Nicholas R, Piccini P. 2012. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
Neurology. 79(6):523-30
De Silva A, Salem V, Matthews PM, Dhillo WS. 2012. The use of functional MRI to study appetite control in the CNS.
Exp Diabetes Res. Volume 2012, Article ID 764017, 13 pages
Colasanti A, Searle GE, Long CJ, Hill SP, Reiley RR, Quelch D, Erritzoe D, Tziortzi AC, Reed LJ, Lingford-Hughes AR,
Waldman AD, Schruers KR, Matthews PM, Gunn RN, Nutt DJ, Rabiner EA. 2012. Endogenous opioid release in thehuman brain reward system induced by acute amphetamine administration. Biol Psychiatry. 72(5):371-7
Tomassini V, Johansen-Berg H, Jbabdi S, Wise RG, Pozzilli C, Palace J, Matthews PM. 2012. Relating brain damage
to brain plasticity in patients with multiple sclerosis. Neurorehabil Neural Repair. 26(6):581-93
Newbould RD, Miller SR, Toms LD, Swann P, Tielbeek JA, Gold GE, Strachan RK, Taylor PC, Matthews PM, Brown
AP. 2012. T2* measurement of the knee articular cartilage in osteoarthritis at 3T. J Magn Reson Imaging. 35(6):1422-9
Cole DM, Beckmann CF, Searle GE, Plisson C, Tziortzi AC, Nichols TE, Gunn RN, Matthews PM, Rabiner EA,
Beaver JD. 2012. Orbitofrontal connectivity with resting-state networks is associated with midbrain dopamine D3
receptor availability. Cereb Cortex. 22(12):2784-93
Stagg CJ, Bachtiar V, O'Shea J, Allman C, Bosnell RA, Kischka U, Matthews PM, Johansen-Berg H. 2012. Corticalactivation changes underlying stimulation-induced behavioural gains in chronic stroke. Brain. 135(1):276-84
Filippini N, Nickerson LD, Beckmann CF, Ebmeier KP, Frisoni GB, Matthews PM, Smith SM, Mackay CE. 2012. Agerelated adaptations of brain function during a memory task are also present at rest. Neuroimage. 59(4):3821-8
Newbould RD, Miller SR, Tielbeek JA, Toms LD, Rao AW, Gold GE, Strachan RK, Taylor PC, Matthews PM, Brown
AP. 2012. Reproducibility of sodium MRI measures of articular cartilage of the knee in osteoarthritis. Osteoarthritis
Cartilage. 20(1):29-35

Gelineau-Morel R, Tomassini V, Jenkinson M, Johansen-Berg H, Matthews PM, Palace J. 2012. The effect of15
hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp.
33(12):2802-14
Inkster B, Rao AW, Ridler K, Filippini N, Whitcher B, Nichols TE, Wetten S, Gibson RA, Borrie M, Kertesz A, Guzman
DA, Loy-English I, Williams J, Saemann PG, Auer DP, Holsboer F, Tozzi F, Muglia P, Merlo-Pich E, Matthews PM.
2012. Genetic variation in GOLM1 and prefrontal cortical volume in Alzheimer’s disease. Neurobiol Aging. 33(3):45765
2011
Owen DR, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC, Innis RB, Pike VW, Reynolds R, Matthews PM,
Parker CA. 2011. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 52(1):24-32
James A, Hough M, James S, Winmill L, Burge L, Nijhawan S, Matthews PM, Zarei M. 2011. Greater white and grey
matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). Schizophr Res. 128(13):91-7
Valsasina P, Rocca MA, Absinta M, Sormani MP, Mancini L, De Stefano N, Rovira A, Gass A, Enzinger C, Barkhof F,
Wegner C, Matthews PM, Filippi M. 2011. A multicentre study of motor functional connectivity changes in patients withmultiple sclerosis. Eur J Neurosci. 33(7):1256-63
Bush WS, McCauley JL, Dejager PL, Dudek SM, Hafler DA, Gibson RA, Matthews PM, Kappos L, Naegelin Y,
Polman CH, Hauser SL, Oksenberg J, Haines JL, Ritchie MD. 2011. A knowledge-driven interaction analysis reveals
potential neurodegenerative mechanism of multiple sclerosis susceptibility. Genes Immun. 12(5):335-40/gene.2011.3
Stagg CJ, Jayaram G, Pastor D, Kincses ZT, Matthews PM, Johansen-Berg H. 2011. Polarity and timing-dependent
effects of transcranial direct current stimulation in explicit motor learning. Neuropsychologia. 49(5):800-4
James A, Hough M, James S, Burge L, Winmill L, Nijhawan S, Matthews PM, Zarei M. 2011. Structural brain andneuropsychometric changes associated with pediatric bipolar disorder with psychosis. Bipolar Disord. 13(1):16-2
Wang JH, Pappas D, De Jager PL, Pelletier D, de Bakker PI, Kappos L, Polman CH, Multiple Sclerosis Genetics
Consortium AA, Chibnik LB, Hafler DA, Matthews PM, Hauser SL, Baranzini SE, Oksenberg JR. 2011. Modeling the
Cumulative Genetic Risk for Multiple Sclerosis from Genome Wide Association Data. Genome Med. 18(1):3
Owen DR, Piccini P, Matthews PM. 2011. Towards molecular imaging of multiple sclerosis. Mult Scler. 17(3):262-72
Dixson L, Ridler K, Nichols TE, Saemann PG, Auer DP, Holsboer F, Muglia P, Matthews PM, Inkster B. 2011. Thyroid
hormone transporter genes and grey matter changes in patients with major depressive disorder and healthy controls.
Psychoneuroendocrinology. 36(6):929-34
Douaud G, Jbabdi S, Behrens TE, Menke RA, Gass A, Monsch AU, Rao A, Whitcher B, Kindlmann G, Matthews PM,
Smith S. 2011. DTI measures in crossing-fibre areas: Increased diffusion anisotropy reveals early white matter
alteration in MCI and mild Alzheimer's disease. Neuroimage. 55(3):880-90
Thomas EL, Makwana A, Newbould R, Rao AW, Gambarota G, Frost G, Delafont B, Mishra RG, Matthews PM, Berk ES,
Schwartz SM, Bell JD, Beaver JD. 2011. Pragmatic study of orlistat 60mg on abdominal obesity. Eur J Clin Nutr.
65(11):1256-62
Bosnell RA, Kincses T, Stagg CJ, Tomassini V, Kischka U, Jbabdi S, Woolrich MW, Andersson J, Matthews PM,
Johansen-Berg H. 2011. Motor practice promotes increased activity in brain regions structurally disconnected after
subcortical stroke. Neurorehabil Neural Repair. 25(7):607-16
Sombekke MH, Jafari N, Bendfeldt K, Mueller-Lenke N, Radue EW, Naegelin Y, Kappos L, Matthews PM, Polman CH,
Barkhof F, Hintzen R, Geurts JJ. 2011. No influence of KIF1B on neurodegenerative markers in multiple sclerosis.
Neurology. 76(21):1843-5
Roosendaal SD, Bendfeldt K, Vrenken H, Polman CH, Borgwardt S, Radue EW, Kappos L, Pelletier D, Hauser SL,
Matthews PM, Barkhof F, Geurts JJ. 2011. Grey matter volume in a large cohort of MS patients; relation to MRIparameters and disability. Mult Scler. 17(9):1098-106
Matthews PM, Rabiner I, Gunn R. 2011. Non-invasive imaging in experimental medicine for drug development. Curr Opin
Pharmacol. 11(5):501-7

Beaver JD, Long CJ, Cole DM, Durcan MJ, Bannon LC, Mishra RG, Matthews PM. 2011. The effects of Nicotine16
replacement on cognitive brain activity during smoking withdrawal studied with simultaneous fMRI/EEG.
Neuropsychopharmacology. 36(9):1792-800
Rabiner EA, Beaver J, Makwana A, Searle G, Long C, Nathan PJ, Newbould RD, Howard J, Miller SR, Bush MA, Hill S,
Reiley R, Passchier J, Gunn RN, Matthews PM, Bullmore ET. 2011. Pharmacological differentiation of opioid receptor
antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans.
Mol Psychiatry. 16(8):826-35
Stagg CJ, Bachtiar V, O'Shea J, Allman C, Bosnell RA, Kischka U, Matthews PM, Johansen-Berg H. 2011. Corticalactivation changes underlying stimulation-induced behavioural gains in chronic stroke. Brain. 135(1):276-84
De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, Ghatei MA, Bloom SR, Matthews PM, Beaver
JD, Dhillo WS. 2011. The gut hormones PYY3-36 and GLP-17-36 amide reduce food intake and modulate brain
activity in appetite centres in humans. Cell Metab. 14(5):700-6
Wahjoepramono EJ, Wijaya LK, Taddei K, Bates KA, Howard M, Martins G, deRuyck K, Matthews PM, Verdile G,
Martins RN. 2011. Direct exposure of guinea pig CNS to human luteinizing hormone increases cerebrospinal fluid andcerebral beta amyloid levels. Neuroendocrinology. 94(4):313-22
Gelineau-Morel R, Tomassini V, Jenkinson M, Johansen-Berg H, Matthews PM, Palace J. 2011. The effect of
hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp.
33(12):2802-14
Zarei M, Mataix-Cols D, Heyman I, Hough M, Doherty J, Burge L, Winmill L, Nijhawan S, Matthews PM, James A.
2011. Changes in gray matter volume and white matter microstructure in adolescents with obsessive-compulsive
disorder. Biol Psychiatry. 70(11):1083-90
Tomassini V, Johansen-Berg H, Leonardi L, Paixão L, Jbabdi S, Palace J, Pozzilli C, Matthews PM. 2011.
Preservation of motor skill learning in patients with multiple sclerosis. Mult Scler. 17(1):103-15
Tomassini V, Jbabdi S, Kincses ZT, Bosnell R, Douaud G, Pozzilli C, Matthews PM, Johansen-Berg H. 2011.
Structural and functional bases for individual differences in motor learning. Hum Brain Mapp. 32(3):494-508
Filippini N, Ebmeier KP, Macintosh BJ, Trachtenberg AJ, Frisoni GB, Wilcock GK, Beckmann CF, Smith SM,
Matthews PM, Mackay CE. 2011. Differential effects of the APOE genotype on brain function across the lifespan.
Neuroimage. 54(1):602-10
Inkster B, Rao AW, Ridler K, Nichols TE, Saemann PG, Auer DP, Holsboer F, Tozzi F, Muglia P, Merlo-Pich E,
Matthews PM. 2011. Structural Brain Changes in Patients with Recurrent Major Depressive Disorder Presenting with
Anxiety Symptoms. J Neuroimaging. 21(4):375-82
2010
Zarei M, Patenaude B, Damoiseaux J, Morgese C, Smith S, Matthews PM, Barkhof F, Rombouts S, Sanz-Arigita E,
Jenkinson M. 2010. Combining shape and connectivity analysis: An MRI study of thalamic degeneration in Alzheimer's
disease. Neuroimage. 49(1):1-8
Giorgio A, Watkins KE, Chadwick M, James S, Winmill L, Douaud G, De Stefano N, Matthews PM, Smith SM,
Johansen-Berg H, James AC. 2010. Longitudinal changes in grey and white matter during adolescence. Neuroimage.
49(1):94-103
Inkster B, Nichols TE, Saemann PG, Auer DP, Holsboer F, Muglia P, Matthews PM. 2010. Pathway-based
approaches to imaging genetics association studies: Wnt signalling, GSK3beta substrates and major depression.
Neuroimage. 53(3):908-17
Heinzen EL, Radtke RA, Urban TJ, Cavalleri GL, Depondt C, Need AC, Walley NM, Nicoletti P, Ge D, Catarino CB,
Duncan JS, Kasperaviciūte D, Tate SK, Caboclo LO, Sander JW, Clayton L, Linney KN, Shianna KV, Gumbs CE,
Smith J, Cronin KD, Maia JM, Doherty CP, Pandolfo M, Leppert D, Middleton LT, Gibson RA, Johnson MR, Matthews
PM, Hosford D, Kälviäinen R, Eriksson K, Kantanen AM, Dorn T, Hansen J, Krämer G, Steinhoff BJ, Wieser HG,
Zumsteg D, Ortega M, Wood NW, Huxley-Jones J, Mikati M, Gallentine WB, Husain AM, Buckley PG, Stallings RL,
Podgoreanu MV, Delanty N, Sisodiya SM, Goldstein DB. 2010. Rare deletions at 16p13.11 predispose to a diverse
spectrum of sporadic epilepsy syndrome. Am J Hum Genet. 86(5):707-18
Owen DR, Howell OW, Tang SP, Wells LA, Bennacef I, Bergstrom M, Gunn RN, Rabiner EA, Wilkins MR, Reynolds R,
Matthews PM, Parker CA. 2010. Two binding sites for [(3)H]PBR28 in human brain: implications for TSPO PET
imaging of neuroinflammation. J Cereb Blood Flow Metab. 30(9):1608-18

Cole DM, Beckmann CF, Long CJ, Matthews PM, Durcan MJ, Beaver JD. 2010. Nicotine replacement in abstinent17
smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics. Neuroimage.
52(2):590-9
Kasperaviciūte D, Catarino CB, Heinzen EL, Depondt C, Cavalleri GL, Caboclo LO, Tate SK, Jamnadas-Khoda J,
Chinthapalli K, Clayton LM, Shianna KV, Radtke RA, Mikati MA, Gallentine WB, Husain AM, Alhusaini S, Leppert D,
Middleton LT, Gibson RA, Johnson MR, Matthews PM, Hosford D, Heuser K, Amos L, Ortega M, Zumsteg D, Wieser
HG, Steinhoff BJ, Krämer G, Hansen J, Dorn T, Kantanen AM, Gjerstad L, Peuralinna T, Hernandez DG, Eriksson KJ,
Kälviäinen RK, Doherty CP, Wood NW, Pandolfo M, Duncan JS, Sander JW, Delanty N, Goldstein DB, Sisodiya SM.
2010. Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study. Brain.
133(7):2136-47
Sloan HL, Austin VC, Blamire AM, Schnupp JW, Lowe AS, Allers KA, Matthews PM, Sibson NR. 2010. Regional
differences in neurovascular coupling in rat brain as determined by fMRI and electrophysiology. Neuroimage.
53(2):399-411
Menke RA, Jbabdi S, Miller KL, Matthews PM, Zarei M. 2010. Connectivity-based segmentation of the substantia
nigra in human and its implications in Parkinson’s disease. Neuroimage. 52(4):1175-80
Wise RG, Pattinson KT, Bulte DP, Rogers R, Tracey I, Matthews PM, Jezzard P. 2010. Measurement of relative
cerebral blood volume using BOLD contrast and mild hypoxic hypoxia. Magn Reson Imaging. 28(8):1129-34
Crofts JJ, Higham DJ, Bosnell R, Jbabdi S, Matthews PM, Behrens TE, Johansen-Berg H. 2010. Network analysis
detects changes in the contralesional hemisphere following stroke. Neuroimage. 54(1):161-9
Baranzini SE, Srinivasan R, Khankhanian P, Okuda DT, Nelson SJ, Matthews PM, Hauser SL, Oksenberg JR,
Pelletier D. 2010. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis.
Brain. 133(9):2603-11
Antoniades A, Matthews PM, Pattichis CS, Galwey NW. 2010. A computationally fast measure of epistasis for 2 SNPs
and a categorical phenotype. Conf Proc IEEE Eng Med Biol Soc. 2010:6194-7
Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, Dixon IJ, Hallett WA, Whitcher B, Brown
AP, Zvartau-Hind M, Lotay N, Lai RY, Castiglia M, Jeter B, Matthews JC, Chen K, Bandy D, Reiman EM, Gold M,
Rabiner EA, Matthews PM. 2010. A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET
for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease. J Alzheimers Dis.
22(4):1241-56
2009
Matthews PM. 2009. Brain imaging of multiple sclerosis: the next 10 years. Neuroimaging Clin N Am. 19(1):101-12
Rocca MA, Absinta M, Valsasina P, Ciccarelli O, Marino S, Rovira A, Gass A, Wegner C, Enzinger C, Korteweg T,
Sormani MP, Mancini L, Thompson AJ, De Stefano N, Montalban X, Hirsch J, Kappos L, Ropele S, Palace J, Barkhof
F, Matthews PM, Filippi M. 2009. Abnormal connectivity of the sensorimotor network in patients with MS: A
multicenter fMRI study. Hum Brain Mapp. 30(8):2412-25
Bendfeldt K, Kuster P, Traud S, Egger H, Winklhofer S, Mueller-Lenke N, Naegelin Y, Gass A, Kappos L, Matthews
PM, Nichols TE, Radue EW, Borgwardt SJ. 2009. Association of regional gray matter volume loss and progression ofwhite matter lesions in multiple sclerosis - A longitudinal voxel-based morphometry study. Neuroimage. 45(1):60-7
Filippini N, Rao A, Wetten S, Gibson RA, Borrie M, Guzman D, Kertesz A, Loy-English I, Williams J, Nichols T,
Whitcher B, Matthews PM. 2009. Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional
cortical atrophy in Alzheimer's disease. Neuroimage. 44 (3): 724-8
Mancini L, Ciccarelli O, Manfredonia F, Thornton JS, Agosta F, Barkhof F, Beckmann C, De Stefano N, Enzinger C,
Fazekas F, Filippi M, Gass A, Hirsch JG, Johansen-Berg H, Kappos L, Korteweg T, Manson SC, Marino S, Matthews
PM, Montalban X, Palace J, Polman C, Rocca M, Ropele S, Rovira A, Wegner C, Friston K, Thompson A, Yousry T.
2009. Short-term adaptation to a simple motor task: a physiological process preserved in multiple sclerosis.
Neuroimage. 45(2):500-11
Lin X, Song K, Lim N, Yuan X, Johnson T, Abderrahmani A, Vollenweider P, Stirnadel H, Sundseth SS, Lai E, Burns
DK, Middleton LT, Roses AD, Matthews PM, Waeber G, Cardon L, Waterworth DM, Mooser V. 2009. Risk predictionof prevalent diabetes in a Swiss population using a weighted genetic score-the CoLaus Study. Diabetologia. 52(4):6008

Zarei M, Damoiseaux JS, Morgese C, Beckmann CF, Smith SM, Matthews PM, Scheltens P, Rombouts SA,18
Barkhof F. 2009. Regional white matter integrity differentiates between vascular dementia and Alzheimer disease.
Stroke. 40(3):773-9
Baranzini SE, Galwey NW, Wang J, Khankhanian P, Lindberg R, Pelletier D, Wu W, Uitdehaag BM; GeneMSA
Consortium, Kappos L, Polman CH, Matthews PM, Hauser SL, Gibson RA, Oksenberg JR, Barnes MR. 2009.
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet.
1(11):2078-90
Stagg CJ, Wylezinska M, Matthews PM, Johansen-Berg H, Jezzard P, Rothwell JC, Bestmann S. 2009. The
Neurochemical Effects of Theta burst Stimulation as assessed by Magnetic Resonance Spectroscopy. Neurophysiol.
101(6):2872-7
Filippini N, Macintosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay
CE. 2009. Distinct patterns of brain activity in young carriers of the APOE-{varepsilon} 4 allele. Proc Natl Acad Sci U S
A. 106(17):7209-14
Stagg CJ, O'Shea J, Kincses ZT, Woolrich M, Matthews PM, Johansen-Berg H. 2009. Modulation of movementassociated cortical activation by transcranial direct current stimulation. Eur J Neurosci. 30(7):1412-23
Inkster B, Nichols TE, Saemann PG, Auer DP, Holsboer F, Muglia P, Matthews PM. 2009. Association of GSK3beta
polymorphisms with brain structural changes in major depressive disorder. Arch Gen Psychiatry. 66(7):721-8
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O,
Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J,
Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B,
Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM,
Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE,
Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA; Genetic Risk and Outcome in
Psychosis (GROUP), Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser
G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM,
Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG, Terenius L, Agartz I, Petursson H,
Nöthen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA.
2009. Common variants conferring risk of schizophrenia. Nature. 460(7256):744-7
De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C,
Briskin R, Romano S; International MS Genetics Consortium, Baranzini SE, McCauley JL, Pericak-Vance MA, Haines
JL, Gibson RA, Naeglin Y, Uitdehaag B, Matthews PM, Kappos L, Polman C, McArdle WL, Strachan DP, Evans D,
Cross AH, Daly MJ, Compston A, Sawcer SJ, Weiner HL, Hauser SL, Hafler DA, Oksenberg JR. 2009. Meta-analysis
of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat
Genet. 41(7):776-82
Voets NL, Adcock JE, Stacey R, Hart Y, Carpenter K, Matthews PM, Beckmann CF. 2009. Functional and structuralchanges in the memory network associated with left temporal lobe epilepsy. Hum Brain Mapp. 30(12):4070-81
Douaud G, Mackay C, Andersson J, James S, Quested D, Ray MK, Connell J, Roberts N, Crow TJ, Matthews PM,
Smith S, James A. 2009. Schizophrenia delays and alters maturation of the brain in adolescence. Brain. 132(9):243748
Enzinger C, Dawes H, Johansen-Berg H, Wade D, Bogdanovic M, Collett J, Guy C, Kischka U, Ropele S, Fazekas F,
Matthews PM. 2009. Brain activity changes associated with treadmill training after stroke. Stroke. 40(7):2460-7
Matthews PM, Comley R. 2009. Advances in molecular imaging of multiple sclerosis. Expert Rev Clin Immunol.
5(6):765-77
Menke RA, Scholz J, Miller KL, Deoni S, Jbabdi S, Matthews PM, Zarei M. 2009. MRI characteristics of the substantia
nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage. 47(2):435-41
Stagg CJ, Best JG, Stephenson MC, O'Shea J, Wylezinska M, Kincses ZT, Morris PG, Matthews PM, Johansen-Berg
H. 2009. Polarity-sensitive modulation of cortical neurotransmitters by transcranial stimulation. J Neurosci.
29(16):5202-6
Antoniades A, Kalvari I, Pattichis C, Jones N, Matthews PM, Domenici E, Muglia P. 2009. Discovering genetic
polymorphism associated with gene expression levels across the whole genome. Conf Proc IEEE Eng Med Biol Soc.
2009:5466-9

Ciccarelli O, Behrens TE, Johansen-Berg H, Talbot K, Orrell RW, Howard RS, Nunes RG, Miller DH, Matthews PM,19
Thompson AJ, Smith SM. 2008. Investigation of white matter pathology in ALS and PLS using tract-based spatial
statistics. Hum Brain Mapp. 30(2):615-24
Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag B, Johnson
MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H,
Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green A,
Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR. 2009.
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet.
18(4):767-78
2008
Giorgio A, Watkins KE, Douaud G, James AC, James S, De Stefano N, Matthews PM, Smith SM, Johansen-Berg H.
2008. Changes in white matter microstructure during adolescence. Neuroimage. 39(1):52-61
Tamás Kincses Z, Johansen-Berg H, Tomassini V, Bosnell R, Matthews PM, Beckmann CF. 2008. Model-freecharacterization of brain functional networks for motor sequence learning using fMRI. Neuroimage. 15(4):1950-8
Dawes H, Enzinger C, Johansen-Berg H, Bogdanovic M, Guy C, Collett J, Izadi H, Stagg C, Wade D, Matthews PM.
2008. Walking performance and its recovery in chronic stroke in relation to extent of lesion overlap with the descending
motor tract. Exp Brain Res. 186(2):325-33
Ciccarelli O, Behrens TE, Johansen-Berg H, Talbot K, Orrell RW, Howard RS, Nunes RG, Miller DH, Matthews PM,
Thompson AJ, Smith SM. 2008. Investigation of white matter pathology in ALS and PLS using tract-based spatial
statistics. Hum Brain Mapp. 30(2):615-24
Wegner C, Filippi M, Korteweg T, Beckmann C, Ciccarelli O, De Stefano N, Enzinger C, Fazekas F, Agosta F, Gass A,
Hirsch J, Johansen-Berg H, Kappos L, Barkhof F, Polman C, Mancini L, Manfredonia F, Marino S, Miller DH,
Montalban X, Palace J, Rocca M, Ropele S, Rovira A, Smith S, Thompson A, Thornton J, Yousry T, Matthews PM.
2008. Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a
multi-centre fMRI study. Eur J Neurol. 15(2):113-22
Manson SC, Wegner C, Filippi M, Barkhof F, Beckmann C, Ciccarelli O, De Stefano N, Enzinger C, Fazekas F, Agosta
F, Gass A, Hirsch J, Johansen-Berg H, Kappos L, Korteweg T, Polman C, Mancini L, Manfredonia F, Marino S, Miller
DH, Montalban X, Palace J, Rocca M, Ropele S, Rovira A, Smith S, Thompson A, Thornton J, Yousry T, Frank JA,
Matthews PM. 2008. Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence fora functional pathology of interhemispheric neuronal inhibition. Exp Brain Res. 187(1):25-31
Enzinger C, Johansen-Berg H, Dawes H, Bogdanovic M, Collett J, Guy C, Ropele S, Kischka U, Wade D, Fazekas F,
Matthews PM. 2008. Functional MRI correlates of lower limb function in stroke victims with gait impairment. Stroke.
39(5):1507-13
Allen HA, Humphreys GW, Matthews PM. 2008. A neural marker of content-specific active ignoring. J Exp Psychol
Hum Percept Perform. 34(2):286-97
Pomeroy IM, Jordan EK, Frank JA, Matthews PM, Esiri MM. 2008. Diffuse cortical atrophy in a marmoset model ofmultiple sclerosis. Neurosci Lett. 30;437(2):121-4
Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, Prinjha RK, Upmanyu R, Kefi M, Zouari M,
Sassi SB, Yahmed SB, El Euch-Fayeche G, Matthews PM, Middleton LT, Gibson RA, Hentati F, Farrer MJ. 2008.
LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol.
7(7):591-4
Matthews PM. 2008. Approaching a renaissance in coma research responsibly. Nat Clin Pract Neurol. 4(10):523
Voets NL, Hough MG, Douaud G, Matthews PM, James A, Winmill L, Webster P, Smith S. 2008. Evidence forabnormalities of cortical development in adolescent-onset schizophrenia. Neuroimage. 43(4):665-75
Knouff CW, Lim N, Song K, Yuan X, Walker MC, Townsend R, Waeber G, Matthews PM, Vollenweider P, Waterworth
DM, Mooser V. 2008. Pharmacological effects of lipid-lowering drugs recapitulate with a larger amplitude thephenotypic effects of common variants within their target genes. Pharmacogenet Genomics. 18(12):1051-1057
Ishihara-Paul L, Hulihan MM, Kachergus J, Upmanyu R, Warren L, Amouri R, Elango R, Prinjha RK, Soto A, Kefi M,
Zouari M, Sassi SB, Yahmed SB, El Euch-Fayeche G, Matthews PM, Middleton LT, Gibson RA, Hentati F, Farrer MJ.
2008. PINK1 mutations and parkinsonism. Neurology. 71(12):896-902

Matthews PM, Radda GK, Johansen-Berg H, Tracey I, Cowey A. 2008. Remembering John Newsom-Davis'20
contribution to human imaging in Oxford. J Neuroimmunol. 201-202:250-4
Stefansson H, Rujescu D, Cichon S, Pietiläinen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson
T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV,
Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T,
Haraldsson M, Magnusdottir BB, Giegling I, Möller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser
G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon E, Di Forti M, Murray R,
Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Mühleisen TW, Wang AG, Ullum H, Djurovic S, Melle I,
Olesen J, Kiemeney LA, Franke B; GROUP, Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A,
Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein DB, Nöthen MM, Peltonen L,
Collier DA, St Clair D, Stefansson K. 2008. Large recurrent microdeletions associated with schizophrenia. Nature.
455(7210):232-6
Cader S, Palace J, Matthews PM. 2008. Cholinergic agonism alters cognitive processing and enhances brain
functional connectivity in patients with multiple sclerosis. J Psychopharmacol. 23:686-96
Bosnell R, Wegner C, Kincses ZT, Korteweg T, Agosta F, Ciccarelli O, De Stefano N, Gass A, Hirsch J, JohansenBerg H, Kappos L, Barkhof F, Mancini L, Manfredonia F, Marino S, Miller DH, Montalban X, Palace J, Rocca M,
Enzinger C, Ropele S, Rovira A, Smith S, Thompson A, Thornton J, Yousry T, Whitcher B, Filippi M, Matthews PM.
2008. Reproducibility of fMRI in the clinical setting: implications for trial designs. Neuroimage. 42(2):603-10
Johansen-Berg H, Gutman DA, Behrens TE, Matthews PM, Rushworth MF, Katz E, Lozano AM, Mayberg HS. 2008.
Anatomical Connectivity of the Subgenual Cingulate Region Targeted with Deep Brain Stimulation for TreatmentResistant Depression. Cereb Cortex. 18(6):1374-83
Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R,
Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P,
Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, Owen MJ,
Plumpton M, Pryse-Phillips W, Prinjha RK, Richardson JC, Saunders A, Slater AJ, St George-Hyslop PH, Stinnett SW,
Swartz JE, Taylor RL, Wherrett J, Williams J, Yarnall DP, Gibson RA, Irizarry MC, Middleton LT, Roses AD. 2008.
Candidate single-nucleotide polymorphisms from a genome wide association study of Alzheimer disease. Arch Neurol.
65(1):45-53
2007
David SP, Munafò MR, Johansen-Berg H, Mackillop J, Sweet LH, Cohen RA, Niaura R, Rogers RD, Matthews PM,
Walton RT. 2007. Effects of Acute Nicotine Abstinence on Cue-elicited Ventral Striatum/Nucleus Accumbens
Activation in Female Cigarette Smokers: A Functional Magnetic Resonance Imaging Study. Brain Imaging Behav. 1(34):43-57
Schlosser RG, Nenadic I, Wagner G, Gullmar D, von Consbruch K, Kohler S, Schultz CC, Koch K, Fitzek C, Matthews
PM, Reichenbach JR, Sauer H. 2007. White matter abnormalities and brain activation in schizophrenia: a combined
DTI and fMRI study. Schizophr Res. 89(1-3):1-11
Zarei M, Johansen-Berg H, Jenkinson M, Ciccarelli O, Thompson AJ, Matthews PM. 2007. Two-dimensional
population map of cortical connections in the human internal capsule. J Magn Reson Imaging. 25(1):48-54
Morgan RM, Parry AM, Arida RM, Matthews PM, Davies B, Castell LM. 2007. Effects of elevated plasma tryptophan onbrain activation associated with the Stroop task. Psychopharmacology (Berl). 90(3):383-9
Bhagwagar L, Wylezinska M, Jezzard P, Evans J, Ashworth F, Sule A, Matthews PM, Cowen PJ. 2007. Reduction in
occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar
subjects. Biol Psychiatry. 61(6):806-12
Matthews PM, Talbot K. 2007. Magnetic resonance spectroscopic imaging--of prognostic value in amyotrophic lateralsclerosis? Nat Clin Pract Neurol. 3(2):76-7
Cader S, Johansen-Berg H, Wylezinska M, Palace J, Behrens TE, Smith S, Matthews PM. 2007. Discordant whitematter N-acetylasparate and diffusion MRI measures suggest that chronic metabolic dysfunction contributes to axonal
pathology in multiple sclerosis. Neuroimage. 36(1):19-27
Matthews PM. 2007. Molecular imaging of brain amyloid in mild cognitive impairment and Alzheimer's disease. NatClin Pract Neurol. 3(7):366-7

Smith SM, Rao A, De Stefano N, Jenkinson M, Schott JM, Matthews PM, Fox NC. 2007. Longitudinal and cross-21
sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage.
36(4):1200-6
Blamire AM, Cader S, Lee M, Palace J, Matthews PM. 2007. Axonal damage in the spinal cord of multiple sclerosis
patients detected by magnetic resonance spectroscopy. Magn Reson Med. 58(5):880-5
Tomassini V, Jbabdi S, Klein JC, Behrens TE, Pozzilli C, Matthews PM, Rushworth MF, Johansen-Berg H. 2007.
Diffusion-weighted imaging tractography-based parcellation of the human lateral premotor cortex identifies dorsal andventral subregions with anatomical and functional specializations. J Neurosci. 27(38):10259-69
Douaud G, Smith S, Jenkinson M, Behrens T, Johansen-Berg H, Vickers J, James S, Voets N, Watkins K, Matthews
PM, James A. 2007. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia.
Brain. 130( 9):2375-86
De Stefano N, Filippi M, Miller D, Pouwels PJ, Rovira A, Gass A, Enzinger C, Matthews PM, Arnold DL. 2007.
Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology. 69(20):1942-52
2006
De Luca M, Beckmann CF, De Stefano N, Matthews PM, Smith SM. 2006. fMRI resting state networks define distinct
modes of long-distance interactions in the human brain. Neuroimage. 29(4):1359-67
Matthews PM, Wise R. 2006. Non-invasive brain imaging for experimental medicine in drug discovery. Expert Op
Drug Discov. 1(2):111-21
Cader S, Cifelli A, Abu-Omar Y, Palace J, Matthews PM. 2006. Reduced brain functional reserve and alteredfunctional connectivity in patients with multiple sclerosis. Brain. 129( 2):527-37
Mottonen R, Calvert GA, Jaaskelainen IP, Matthews PM, Thesen T, Tuomainen J, Sams M. 2006. Perceiving
identical sounds as speech or non-speech modulates activity in the left posterior superior temporal sulcus.
Neuroimage. 30(2):563-9
Whitcher B, Matthews PM. 2006. Noninvasive brain imaging for experimental medicine in drug discovery anddevelopment: promise and pitfalls. Int J Pharm Med. 20(3):167-175
Devlin JT, Sillery EL, Hall DA, Hobden P, Behrens TE, Nunes RG, Clare S, Matthews PM, Moore DR, Johansen-Berg
H. 2006. Reliable identification of the auditory thalamus using multi-modal structural analyses. Neuroimage.
30(4):1112-20
Enzinger C, Smith S, Fazekas F, Drevin G, Ropele S, Nichols T, Behrens T, Schmidt R, Matthews PM. 2006. Lesion
probability maps of white matter hyperintensities in elderly individuals: Results of the Austrian stroke prevention study.
J Neurol. 253(8):1064-70
Smith SM, Jenkinson M, Johansen-Berg H, Rueckert D, Nichols TE, Mackay CE, Watkins KE, Ciccarelli O, Cader MZ,
Matthews PM, Behrens TE. 2006. Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data.
Neuroimage. 31(4):1487-505 [2011 Award Winner: most highly cited paper in Neuroimage 2006-2010]
Ciccarelli O, Behrens TE, Altmann DR, Orrell RW, Howard RS, Johansen-Berg H, Miller DH, Matthews PM,
Thompson AJ. 2006. Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in
amyotrophic lateral sclerosis. Brain. 129(7):1859-71
Farrugia ME, Robson MD, Clover L, Anslow P, Newsom-Davis J, Kennett R, Hilton-Jones D, Matthews PM, Vincent A.
2006. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia
gravis. Brain. 129( 6):1481-92
Selvaraj S, Wylezinska M, Evans J, Jezzard P, Matthews PM, Cowen PJ. 2006. Tryptophan depletion does not lower
brain GABA levels in healthy volunteers. Psychopharmacology (Berl). 187(1):131-2
Ciccarelli O, Toosy AT, Marsden JF, Wheeler-Kingshott CM, Miller DH, Matthews PM, Thompson AJ. 2006.
Functional response to active and passive ankle movements with clinical correlations in patients with primary
progressive multiple sclerosis. J Neurol. 253(7):882-91
Devlin JT, Jamison HL, Gonnerman LM, Matthews PM. 2006. The role of the posterior fusiform gyrus in reading. J
Cogn Neurosci. 18(6):911-22

Matthews PM, Honey GD, Bullmore ET. 2006. Applications of fMRI in translational medicine and clinical practice.22
Nat Rev Neurosci. 7(9):732-44
Zarei M, Johansen-Berg H, Smith S, Ciccarelli O, Thompson AJ, Matthews PM. 2006. Functional anatomy ofinterhemispheric cortical connections in the human brain. J Anat. 209(3):311-20
Manson SC, Palace J, Frank JA, Matthews PM. 2006. Loss of interhemispheric inhibition in patients with multiple
sclerosis is related to corpus callosum atrophy. Exp Brain Res. 174(4):728-33
Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. 2006. Neocortical neuronal, synaptic, and glial loss in
multiple sclerosis. Neurology. 67(6):960-7
Abu-Omar Y, Cader S, Guerrieri Wolf L, Pigott D, Matthews PM, Taggart DP. 2006. Short-term changes in cerebral
activity in on-pump and off-pump cardiac surgery defined by functional magnetic resonance imaging and theirrelationship to microembolization. J Thorac Cardiovasc Surg. 132(5):1119-25
Floyer-Lea A, Wylezinska M, Kacsis T, Matthews PM. 2006. Rapid modulation of GABA concentration in humansensorimotor cortex during motor learning. J Neurophysiol. 95(3):1639-44
Jamison HL, Watkins KE, Bishop DV, Matthews PM. 2006. Hemispheric specialization for processing auditory
nonspeech stimuli. Cereb Cortex. 16(9):1266-75
2005
Voets NL, Adcock JE, Flitney DE, Behrens TE, Hart Y, Stacey R, Carpenter K, Matthews PM. 2005. Distinct rightfrontal lobe activation in language processing following left hemisphere injury. Brain. 129(3):754-66
Ciccarelli O, Toosy AT, Marsden JF, Wheeler-Kingshott CM, Sahyoun C, Matthews PM, Miller DH, Thompson AJ.
2005. Identifying brain regions for integrative sensorimotor processing with ankle movements. Exp Brain Res.
166(1):31-42
Smith SM, Beckmann SF, Ramnani N, Woolrich MW, Bannister PR, Jenkinson M, Matthews PM, McDonigle DJ. 2005.
Variability in fMRI: a re-examination of inter-session differences. Hum Brain Mapp. 24(3):248-57
Austin VC, Blamire AM, Allers K, Sharp T, Styles P, Matthews PM, Sibson NR. 2005. Confounding effects of anesthesia
on functional activation in rodent brain study of halothane and alpha-chloralose anesthesia. Neuroimage. 24(1):92-100
Enzinger C, Fazekas, F, Matthews PM, Ropele SM, Schmidt R. 2005. Risk factors for the progression of brain atrophy innormal ageing 6 year follow-up of the Austrian Stroke Prevention Study (ASPS). Neurology. 64(10):1704-1711
Johansen-Berg H, Behrens TEJ, Sillery E, Ciccarelli O, Thompson A, Smith, S, Matthews PM. 2005. Functionalanatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus.
Cerebral Cortex. 15(1):31-9
Devlin JT, Rushworth MF, Matthews PM. 2005. Category-related activation for written words in the posterior fusiform is
specific. Neuropsychologia. 43(1):69-74
Osterbauer RA, Matthews PM, Jenkinson M, Beckmann CF, Hansen PC, Calvert GA. 2005. The color of scents:
chromatic stimuli modulate odor responses in the human brain. J Neurophysiol. 93(6): 3434-41
Tjandra T, Brooks JCW, Figueiredo P, Wise RG, Matthews PM, Tracey I. 2005. Quantitative assessment of the
reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design.
Neuroimage. 27(2):393:401
Bridge H, Clare S, Jenkinson M, Jezzard, P, Parker A, Matthews PM. 2005. Independent anatomical and functional
measures of the V1/V2 boundary in human visual cortex. Vision Research. 5(2):93-102
Olivers CNL, Smith SS, Matthews PM, Humphries GW. 2005. Prioritizing new over old: an fMRI study of the preview
search task. Human Brain Mapping. 24(1):69-78
Floyer-Lea A, Matthews PM. 2005. Distinguishable brain activation networks for short and long-term motor skill learning.
J Neurophysiol. 94(1):512-8
Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt H, Matthews PM, Fazekas F. 2005. White matter lesion
progression, brain atrophy and cognitive decline. The Austrian Stroke Prevention Study. J Neurol. 253(8):1064-70

Ramnani N, Behrens TE, Johansen-Berg H, Richter MC, Pinsk MA, Andersson JL, Rudebeck, P, Ciccarelli O, Richter23
W, Thompson AJ, Gross CG, Robson MD, Kastner S, Matthews PM. 2005. The evolution of prefrontal inputs to thecortico-pontine system: Diffusion imaging evidence from macaque monkeys and humans. Cereb Cortex. 16(6):811-8
Iannetti GD, Nazy RK, Wise RG, Jezzard P, Brooks JC, Zambreanu L, Vennart W, Matthews PM, Tracey I. 2005.
Simultaneous recording of laser-evoked brain potentials and continuous, high-field functional magnetic resonance imaging
in humans. Neuroimage. 28(3):708-19
Pomeroy IM, Matthews PM, Frank JA Jordan EK, Esiri MM. 2005. Demyelinated neocortical lesions in marmoset
autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain. 128(11):2713-21
David SP, Munafo MR, Johansen-Berg H, Smith SM, Rogers RD, Matthews PM, Walton RT. 2005. Ventral
Striatum/Nucleus Accumbens Activation to Smoking-Related Pictorial Cues in Smokers and Non-smokers: A
Functional Magnetic Resonance Imaging Study. Biol Psychiatry. 58(6):488-94
Basoah A, Matthews PM, Morten KJ. 2005. Rapid rates of newly synthesized mitochondrial protein degradation are
significantly affected by the generation of mitochondrial free radicals. FEBS Lett. 579(28):6511-7
De Luca M, Smith S, De Stefano N, Federico A, Matthews PM. 2005. Blood oxygenation level dependent contrast
resting state networks are relevant to functional activity in the neocortical sensorimotor system. Exp Brain Res.
167(4):587-94
2004
Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews PM, Cowen PJ. 2004. Increased brain GABA
concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry. 161(2):36870
Abu-Omar Y, Piggott DW, Matthews PM, Taggart DP. 2004. Solid and gaseous cerebral microembolisation during offpump, on-pump and open cardiac surgery. J Thoracic Cardiovascular Surg. 127(6):1759-65
Enzinger C, Ropele S, Smith S, Strasser-Fuchs S, Poltrum B, Schmidt H, Matthews PM, Fazekas F. 2004.
Accelerated evolution of brain atrophy and “black holes” in MS patients with APOEε4. Ann Neurol. 55(4):563-9
Arthurs OJ, Johansen-Berg, H Matthews PM, Boniface SJ. 2004. Attention differentially modulates coupling of fMRI
BOLD and evoked potential signal amplitudes in human somatosensory cortex. Exp. Brain. Res. 157(3):269-74
Matthews PM. 2004. An update on neuroimaging of multiple sclerosis. Curr Opin Neurol. 17(4):453-8
Saini S, DeStefano N, Smith S, Guidi L, Amato MP, Federico A, Matthews PM. 2004. Altered cerebellar functional
connectivity mediates potential adaptive plasticity in patients with MS. J. Neurol. Neurosurg. Psych. 75(6):840-46
Floyer-Lea A, Matthews PM. 2004. Changing brain networks for visuomotor control with increased movement
automaticity. J Neurophysiol. 92(4):2405-12
Sahyoun C, Floyer-Lea A, Johansen-Berg H, Matthews PM. 2004. Towards an understanding of gait control: brain
activation during the anticipation, preparation and execution of foot movements. Neuroimage. 21(2):568-75
Abu-Omar Y, Cifelli A, Matthews PM, Taggart DP. 2004. The role of microembolisation in cerebral injury as defined byfunctional magnetic imaging. European journal of Cardio-Thoracic Surgery. 26(3):586-591
Vollm BA, DeAraujo IE, Cowen PJ, Rolls ET, Kringelbach ML, Smith KA, Jezzard P, Heal RJ, Matthews PM. 2004.
Metamphetamine activates reward circuitry in drug anive human subjects. Neuropsychopharmacology. 29(9):1715-22
Devlin JT, Jamison HL, Matthews PM, Gonnerman LM. 2004. Morphology and the internal structure of words. Proc
Natl Acad Sci U S A. 101(41):14984-8
Ramnani N, Behrens TEJ, Penny W, Matthews PM. 2004. New approaches for exploring anatomical and functional
connectivity in the human brain. Biol Psych. 56(9):613-9
Chen JT, Narayanan S, Collins DL, Smith SM, Matthews PM, Arnold DL. 2004. Relating MRI detectable neocortical
pathology to disability progression in multiple sclerosis using MRI. NeuroImage. 23(3):1168-75
Matthews PM, Johansenberg H, Reddy H. 2004. Non-invasive mapping of brain function and brain recovery; applying
lessons from cognitive neuroscience to neurorehabilitation. Restorative Neurol Neurosci. 22(3-5):245-60

Cardillo ER, Aydelott J, Matthews PM, Devlin JT. 2004. Left inferior prefrontal cortex activity reflects inhibitory rather24
than facilitatory priming. J Cog Neurosci. 16(9):1552-61
Miller DH, Filippi M, Fazekas F, Frederiksen JL, Matthews PM, Montalban X, Polman CH. 2004. Role of magnetic
resonance imaging within diagnostic criteria for multiple sclerosis. Ann Neurol. 56(2):273-278
Johansen-Berg H, Behrens TEJ, Robson, MD, Drobnjak I, Rushworth MFS, Brady JM, Smith SM, Higham DJ, Matthews
PM. 2004. Changes in connectivity profiles define functionally-distinct regions in human medial frontal cortex. Proc Natl
Acad Sci USA. 101(36):13335-40
Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TEJ, Johansen-Berg H, Bannister PR, De Luca M,
Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM. 2004.
Advances in functional and structural MR image analysis and implementation as FSL. NeuroImage. 23 Suppl 1:S208S219
Matthews PM. 2004. Primary progressive multiple sclerosis takes centre stage. J Neurol Neurosurg Psychiatry.
75(9):1232-3
2003
Wylezinska M, Cifelli A, Jezzard P, Palace J, Alecci M, Matthews PM. 2003. Thalamic Neurodegeneration in relapsing-remitting multiple sclerosis. Neurology. 60(12):1949-54
Parry A, Clare S, Jenkinson M, Smith S, Palace J, Matthews PM. 2003. MRI TI relaxation time changes in MS patients
increase over time in both the white matter and the cortex. J Neuroimaging 13(3):234-9
Behrens TEJ, Johansen-Berg H, Woolrich MW, Smith SM, Wheeler-Kingshott CAM, Boulby PA, Barker GJ, Sillery EL,
Sheehan K, Ciccarelli O, Thompson AJ, Brady JM, Matthews PM. 2003. Non-invasive mapping of connections
between human thalamus and cortex using diffusion imaging. Nature Neurosci. 6(7):750-57
Parry AMM, Scott RB, Palace J, Smith SM, Matthews PM. 2003. Potentially adaptive functional changes of cognitive
processing in patients with multiple sclerosis and their acute modulation by Rivastigmine. Brain. 126(12):2750-60
Behrens TEJ, Woolrich MW, Jenkinson M, Johansen-Berg H, Nunes RG, Clare S, Matthews PM, Brady JM, Smith
SM. 2003. Characterisation and propagation of uncertainty in diffusion weighted MR imaging. Magn Reson Med.
50(5):1077-88
Narain C, Scott S, Wise R, Rosen S, Leff A, Iversen S, Matthews PM. 2003. Defining a left-lateralised response
specific to intelligible speech using fMRI. Cerebral Cortex. 13(12):1362-8
Matthews PM, Jezzard P. 2003. Functional magnetic resonance imaging. J Neurol Neursurg Psych. 75:6-12
Parry A, Matthews PM. 2003. Roles for imaging in understanding the pathophysiology, clinical evaluation, andmanagement of patients with mitochondrial disease. J Neuroimaging. 13(4):293-302
Devlin JT, Raley J, Tunbridge E, Lanary K, Anna Floyer-Lea A, Narain C, Cohen I, Behrens T, Jezzard P, Matthews
PM, Moore DM. 2003. Functional asymmetry for auditory processing in human primary auditory cortex. J Neurosci.
23(37):11516-22
2002
Stevenson VL, Smith SS, Matthews PM, Miller DH, Thompson AJ. 2002. Monitoring disease activity and progression inprimary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral
atrophy. Neurology. 249(2):171-177
Reddy H, De Stefano N, Mortilla M, Federico A, Matthews PM. 2002. Functional reorganisation of the motor cortex
increases with greater axonal injury from CADASIL. Stroke. 33(2):502-508
Johansen-Berg H, Matthews PM. 2002. Attention to movement modulates activity in sensorimotor areas, including
primary motor cortex. Exp Brain Res. 142(1):13-24
Reddy H, Bendahan D, Lee MA, Johansen-Berg H, Donaghy M, Hilton-Jones D, Matthews PM. 2002. An expanded
cortical representation for hand movement after peripheral motor denervation. J Neurol Neurosurg Psychiatry. 72(2):203210
Parry A, Clare S, Jenkinson M, Smith SM, Palace J, Matthews PM. 2002. White matter and lesion T1 relaxation times
increase in parallel and correlate with disability in multiple sclerosis. J Neurol. 249(9):1279-1286

Chen Y, Fu S, Iversen SD, Smith SM, Matthews PM. 2002. Testing for dual brain processing routes in reading: a direct25
contrast of Chinese character and pinyin using fMRI. J Cogn Neurosci. 14(7):1088-1098
Rocca MA, Matthews PM, Caputo D, Ghezzi A, Falini A, Scotti G, Comi G, Filippi M. 2002. Evidence for widespread
movement-associated functional MRI changes in patients with PPMS. Neurology. 58(6):866-872
Andrews TJ, Schluppeck D, Homfray D, Matthews, PM, Blakemore C. 2002. Activity in the fusiform gyrus predicts
conscious perception of Rubin’s vase-face illusion. Neuroimage. 17:890-901
Tracey I, Ploghaus A, Gati JS, Clare S, Smith S, Menon RS, Matthews PM. 2002. Imaging attentional modulation of painin the periaqueductal gray in humans. J Neuroscience. 22(7):2748-2752
Fu S, Chen Y, Smith SM, Iversen S, Matthews PM. 2002. Effects of word form on brain processing of written Chinese.
Neuroimage. 17(3):1538-1548
Pineiro R, Pendlebury S, Johansen-Berg H, Matthews PM. 2002. Altered haemodynamic responses in patients after
subcortical stroke measured by FMRI. Stroke. 33:103-109
Smith K, Ploghaus A, Cowen PJ, McCleery JM, Goodwin GM, Smith S, Tracey I, Matthews PM. 2002. Cerebellar
responses during anticipation of noxious stimuli in subjects recovered from depression. Brit J of Psych. 181(5):411-415
Parry A, Corkill R, Blamire A, Palace J, Narayanan S, Arnold D, Styles P, Matthews PM. 2002. Beta-interferon treatment
does not immediately slow the progression of axonal injury in multiple sclerosis. J Neurol. 250(2):171-8
Devlin J, Matthews PM, Rushworth MFS. 2002. Semantic processing in Broca’s area: a combined fMRI and TMS study.
J Cogn Neurosci. 15(1):71-84
Johansen-Berg H, Dawes H, Guy C, Smith SM, Wade DT, Matthews PM. 2002. Correlation between motor
improvements and altered fMRI activity after rehabilitative therapy. Brain. 125(12):2731-2742
Reddy H, Narayanan S, Woolrich M, Mitsumori T. Lapierre Y, Arnold DL, Matthews PM. 2002. Functional brain
reorganisation for hand movement in patients with multiple sclerosis: defining distinct effects of injury and disability.
Brain. 125(12):2646-2657
Adcock JE, Wise RG, Oxbury JM, Oxbury SM, Matthews PM. 2002. Quantitative fMRI assessment of the differencesin lateralisation of language-related brain activation in patients with temporal lobe epilepsy. Neuroimage. 18(2):423-38
Lee AC, Robbins TW, Smith S, Calvert GA, Tracey I, Matthews PM, Owen AM. 2002. Evidence for asymmetricfrontal-lobe involvement in episodic memory from functional magnetic resonance imaging and patients with unilateralfrontal-lobe excisions. Neuropsychologia. 40:2420-2437
De Stefano N, Matthews PM, Filippi M, Agosta F, De Luca M, Bartolozzi ML, Guidi L, Ghezzi A, Montanari E, Cifelli A,
Federico A, Smith SM. 2002. Evidence of early cortical atrophy in MS: relevance to white matter changes anddisability. Neurology. 60(7):1157-1162
Matthews PM, Adcock J, Chen Y, Fu S, Devlin J, Rushworth M, Smith S, Beckmann C, Iversen S. 2002. Towards
understanding language organisation in the brain using fMRI. Human Brain Mapping. 18(3):239-47
Johansen-Berg H, Rushworth MFS, Bogdanovic MD, Kischka U, Wimalaratna S, Matthews PM. 2002. The role ofipsilateral premotor cortex in hand movement after stroke. Proc Natl Acad Sci. 99(22):14518-23
Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J. Matthews PM. 2002. Thalamic neurodegeneration in multiple
sclerosis. Ann Neurol. 52(5):650-653
2001
Ploghaus A, Narain C, Beckmann CF, Clare S, Bantick S, Wise R, Matthews PM, Rawlins JP, Tracey I. 2001.
Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci. 21(24):9896-9903
De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia C, Antel JP, Matthews PM, Arnold DL. 2001. Evidenceof axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 58:65-70
Matthews PM, De Stefano N, Fazekas F, Filippi M, Miller D, Seitz R. 2001. The future of magnetic resonance-based
techniques in neurology. Eur J Neurol. 8(1):17-25
Matthews PM, Arnold DL. 2001. Magnetic resonance imaging of multiple sclerosis: new insights linking pathology toclinical evolution. Curr Opin Neurol. 14(3):279-287

Matthews PM, Wylezinsa M, Cadoux-Hudson T. 2001. Novel approaches to imaging brain tumours. Hem Onc Clin N26
Am. 15(4):609-630
Smith S, De Stefano N, Jenkinson M, Matthews PM. 2001. Normalised accurate measurement of longitudinal brainchange. J Comput Axial Tomog. 25(3):466-75
Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. 2001. Size-selective neuronal changes in theanterior optic pathways suggest differential susceptibility to injury in multiple sclerosis. Brain. 124(9):1813-20
Smith SM, Zhang Y, Jenkinson M, Chen J, Matthews PM, Federico A, De Stefano N. 2001. Accurate, robust andautomated longitudinal and cross-sectional brain change analysis. Neuroimage. 17(1):479-89
Reddy H, Floyer A, Donaghy M, Matthews PM. 2001. Altered cortical activation with finger movement after peripheral
denervation: comparison of active and passive tasks. Exp Brain Res. 138(4):484-91
Austin VC, Blamire AM, Grieve SM, O’Neill MJ, Styles P, Matthews PM, Sibson NR. 2001. Difference in the BOLD fMRI
response to direct and indirect cortical stimulation in the rat. Magn Reson Med. 49(5):838-847
2000
Taivassalo I, Reddy H, Matthews PM. 2000. Muscle responses to exercise in health and disease. Neurol Clin N Am.
18(1):15-34
Calvert GA, Brammer MJ, Morris R, Williams, SCR, King N, Matthews PM. 2000. Using FMRI to study recovery fromacquired dysphasia. Brain and Language. 71(3):391-399
Pendlebury ST, Lee MA, Blamire AM, Styles P, Matthews PM. 2000. Correlating magnetic resonance imaging markers ofaxonal injury demyelination in motor impairment secondary to stroke and multiple sclerosis. Magn Reson Imag. 18(4):36978
Devlin JT, Russell RP, Davis MH, Price CJ, Wilson J, Moss H E, Matthews PM, Tyler LK. 2000. Susceptibility induced
loss of signal: comparing PET and FMRI on a semantic task. NeuroImage. 11(6. 1):589-600
Evangelou N, Konz D, Esiri M, Smith S, Palace J, Matthews PM. 2000. Regional axonal loss in the corpus callosum
correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain. 123(9):1845-9
Arnold DL, De Stefano N, Narayanan, Matthews PM. 2000. Proton MR spectroscopy in multiple sclerosis. Neuroimag
Clin N Am. 10(4):789-98
Reddy H, Narayanan S, Matthews PM, Huge R, Pike B, Duquesne P, Antel J, Arnold DL. 2000. Relating axonal injury tofunctional recovery in multiple sclerosis. Neurology. 54(1):236-9
Reddy H, Narayanan S, Arnoutelis R, Jenkinson M, Antel J, Matthews PM, Arnold DL. 2000. Evidence for adaptivefunctional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain. 123(11):2314-20
Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. 2000. Quantitative pathological evidence for axonal loss innormal-appearing white matter in multiple sclerosis. Ann Neurol. 47(3):391-395
Lee M, Reddy H, Johansen-Berg H, Pendlebury S, Jenkinson M, Smith S, Palace J, Matthews PM. 2000. The motor
cortex shows adaptive functional changes to brain injury from multiple sclerosis. Ann Neurol. 47(5):606-13
Piniero R, Pendlebury ST, Smith S, Flitney D, Blamire AM, Styles P, Matthews PM. 2000. Relating MR imaging changes
to motor deficit after ischaemic stroke by segmentation of functional motor pathways. Stroke. 31(3):672-9
Lee MS, Blamire AM, Pendlebury S, Ho K-H, Mills K, Styles P, Palace J, Matthews PM. 2000. Axonal injury or loss in theinternal capsule and motor impairment in multiple sclerosis. Arch Neurol. 57(1):65-70
Johansen-Berg H, Christensen V, Woolrich M, Matthews PM. 2000. Attention to touch modulates activity in both primaryand secondary somatosensory areas. Neuroreport. 11(6):1237-41
Reddy H, Lassonde M, Bernasconi N, Bernasconi A, Matthews PM, Andermann F, Arnold DL. 2000. An fMRI study of thelateralisation of motor cortex activation in acallosal patients. Neuroreport. 11(11):2409-13
Ploghaus A, Tracey I, Clare S, Gati JS, Rawlins JN, Matthews PM. 2000. Learning about pain: the neural substrate of theprediction error for aversive events. Proc Natl Acad Sci U S A. 97(16):9281-6

Pineiro R, Pendlebury S, Johansen-Berg H, Matthews PM. 2000. Functional MRI detects posterior shifts in primary27
sensorimotor cortex activation after stroke. Evidence of local adaptive reorganisation? 2000. Stroke. 32(5):1134-1139
1999
Nagy Z, Esiri M, LeGris M, Matthews PM.1999. Mitochondrial enzyme expression in the hippocampus in relation to
Alzheimer-type pathology. Arch Neuropathol. 97(4):346-354
Griffin JL, Rae C, Radda G, Matthews PM. 1999. Lactate-induced inhibition of glucose catabolism in guinea pig corticalbrain slices. Neurochem Int. 35(5):405-9
Pendlebury ST, Blamire AM, Lee MA, Styles P, Matthews PM. 1999. Axonal injury in the internal capsule correlates withmotor impairment after stroke. Stroke. 30(5):956-962
13

Griffin JL, Rae C, Radda GK, Matthews PM. 1999. Delayed labelling of brain glutamate after an intra-arterial C glucose
bolus: evidence for aerobic metabolism of guinea pig glycogen stores. Biochem Biophys Acta. 1450(3):297-307
Ploghaus A, Tracey I, Gati J, Clare S, Menon RS, Matthews PM, Rawlins JNP.1999. Dissociating pain from its
anticipation in the human brain. Science. 284(5422):1979-81
De Stefano N, Narayanan S, Matthews PM, Francis G, Antel J, Arnold DL. 1999. In vivo evidence for axonal dysfunction
remote from focal cerebral demyelination. Brain. 122(10):1933-9
Morten KJ, Beattie P, Brown GK, Matthews PM. 1999. Dichloroacetate stabilizes the mutant E1 subunit in pyruvate
dehydrogenase deficiency. Neurology. 53(3):612-6
Lee MA, Smith S, Palace J, Narayanan S, Silver N, Minicucci L, Filippi M, Miller DH, Arnold DL, Matthews PM. 1999.
Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct
mechanisms of lesion genesis? Brain. 122(7):1261-70
Matthews PM, Clare S, Adcock J. 1999. Functional magnetic resonance imaging, clinical applications and potential. J
Inherit Metab Dis. 22(4):337-52
Matthews PM. 1999. MRI and the management of multiple sclerosis. Neurology. 58(8.4):S23-31
1998
Fu L. Matthews PM, De Stefano N, Worsley KJ, Narayanan S, Francis G, Antel J, Wolfson T, Arnold DL. 1998. Imaging
axonal damage of normal- appearing white matter in multiple sclerosis. Brain. 121(1):103-113
Taivassalo T, DeStefano N, Argov Z, Matthews PM, Chen J, Genge A, Karpati G, Arnold DL. 1998. Effects of aerobic
training in patients with mitochondrial myopathy. Neurology. 50(4):1055-60
DeStefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis G, Antel J, Arnold DL. 1998. Axonal damage
correlates with disability in patients with relapsing- remitting multiple sclerosis. Results of a longitudinal magnetic
resonance spectroscopy study. Brain. 121(8):1469-77
Griffin JL, Rae C, Dixon RM, Radda GK, Matthews PM. 1998. Excitatory amino acid synthesis in hypoxic brain slices:does alanine act as a substrate for glutamate production in hypoxia? J Neurochem. 71(6):2477-2486
Matthews PM, De Stefano N, Narayanan S, Francis GS, Wolinsky JS, Antel JP, Arnold DL. 1998. Putting MRS studies incontext: axonal damage and disability in MS. Sem Neurol. 51:327-36
Lee M, Smith S, Palace J, Matthews PM. 1998. Defining MS disease activity using MRI T2-weighted difference imaging.
Brain. 121(11):2095-2102
Morten KJ, Caky M, Matthews PM. 1998. Mechanisms of expression of pyruvate dehydrogenase deficiency caused by an
E1 subunit mutation. Neurology. 51(5):1324-30
Morten KJ, Caky M, Matthews PM. 1998. Stabilization of the pyruvate dehydrogenase E1 subunit by dichloroacetate.
Neurology. 51(5):1331-5
1997
Narayanan S, Fu L, Pioro E, DeStefano N, Collins DL, Francis G S, Antel JP, Evans AC, Matthews PM, Arnold DL. 1997.
Imaging of axonal damage in multiple sclerosis: spatial distribution of MRI lesions and associated axonal damage. Ann
Neurol. 41(3):385-391

DeStefano N, Matthews PM, Fu L, Francis G, Antel J, Arnold DL. 1997. Axonal dysfunction and disability in a relapse28
of multiple sclerosis. Neurology. 49(4):1138-1141
Cendes F, Andermann F, Dubeau F, Matthews PM, Arnold DL. 1997. Normalisation of neuronal metabolic dysfunction
after surgery for temporal lobe epilepsy. Neurology. 49(6):1525-1533
1996
DeStefano N, Argov Z, Matthews PM, Karpati G, Arnold DL. 1996. Impairment of muscle mitochondrial oxidative
metabolism in McArdle's Disease. Muscle and Nerve. 19(6):764-769
Matthews PM, Narayanen S, DeStefano N, Fu L, Pioro E, Francis G, Antel J, Arnold DL. 1996. Assessment of lesion
pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain.
119(3):715-722
Taivassalo T, Matthews PM, DeStefano N, Sripathi N, Genge A, Karpati G, Arnold DL. 1996. Combined aerobic training
and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase
deficiency. Neurology. 47(2):529-534
1995
Matthews PM, Benjamin D, Bakel I, Squier MV, Nicholson L, Sewry C, Barnes P, Hopkin J, Hendricks R, Brown R,
Hilton-Jones D, Boyd Y, Brown GK, Craig IW. 1995. Muscle X-inactivation patterns and dystrophin expression in
Duchenne muscular dystrophy carriers. Neuromusc Disord. 5(3):209-220
Matthews PM, Donaghy M, Squier W, Chalk C. 1995. Mitochondrial abnormalities are not invariably found in neurologic
syndromes associated with multiple symmetric lipomatosis. Neurology. 45(1):197-98
De Stefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL. 1995. Short-term dichloroacetate treatment
improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology. 45(6):1193-98
Dandurand RJ, Matthews PM, Arnold DL, Eidelman D. 1995. Mitochondrial disease: Pulmonary function, exercise
performance, and blood lactate levels. Chest. 108(1):182-89
Matthews PM, Brown R, Morton K, Marchington D, Poulton J, Brown G. 1995. Intracellular heteroplasmy for diseaseassociated point mutations of mtDNA: implications for disease expression and evidence for mitotic segregation ofheteroplasmic units of mtDNA. Human Genetics. 96(3):261-68
DeStefano N, Matthews PM, Arnold DL. 1995. Reversible decreases in N-acetyl aspartate after acute brain injury. Magn
Reson Med. 34(5):721-27
DeStefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. 1995. Chemical pathology of acute demyelinating
lesions and its correlation with disability. Ann Neurol. 38(6):901-9
Otero L, Brown GK, Silver K, Arnold DL, Matthews PM. 1995. Association of cerebral dysgenesis and lactic acidemia
with X-linked PDH E1 alpha subunit mutations in females. Ped Neurol. 13(4):327-332
1994
Shevell M, Matthews PM, Scriver CR, Brown R, Otero L, LeGris M, Brown GK, Arnold DL. 1994. Cerebral dysgenesis
and lactic acidemia: an MRI/MRS phenotype associated with pyruvate dehydrogenase deficiency. Ped Neurol. 11(3):22429
Matthews PM, Nagy Z, Land J, Brown GK, Squier MV.1994. Isolated capillary proliferation in Leigh's Syndrome. Clin
Neuropath. 13(3):139-141
Matthews PM, Hopkin J, Brown RM, Stephenson JD, Hilton-Jones D, Brown GK. 1994. Comparison of the relative levelsof the 3243 (A>G) mutation in heteroplasmic adult and fetal tissues. J Med Genet. 31(1):41-44
Matthews PM, Otero L, Marchington D, Brown R, LeGris M, Howes R, Meadows L, Shevell M, Scriver C, Brown GK.
1994. Pyruvate dehydrogenase deficiency. Clinical presentation and molecular genetic characterisation of five newpatients. Brain. 117(3):435-443
Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, Antel JP. 1994. Use of proton magnetic
resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol. 36(1):76-82
Fujii T, Van Coster R, Old SE, Medori R, Winter S, Gubits RM, Matthews PM, Brown RM, Brown GK, Dahl HH, DeVivo
DC. 1994. Pyruvate dehydrogenase deficiency: molecular basis for intrafamilial heterogeneity due to a point mutation inexon 4 of the E1-alpha gene. Ann Neurol. 36(1):83-9

1993
29
Moorman CM, Elston JS, Matthews PM. 1993. Leber's Hereditary optic atrophy as a cause of severe visual loss inchildhood. Pediatrics. 91(5):988-89
Matthews PM, Marchington D, Land J, Squire W, Brown R, Brown GK. 1993. Molecular genetic characterisation of an Xlinked form of Leigh's syndrome. Ann Neurol. 33(6):652-5
Matthews PM, Otero L, Marchington D, Leonard J, Brown R, Brown GK. 1993. Neurodevelopmental abnormalities andlactic acidosis in a girl with a 20-bp deletion in the X-linked pyruvate dehydrogenase E1-alpha subunit gene. Neurology.
43(10):2025-30
Matthews PM, Andermann F, Silver K, Karpati G, Arnold DL. 1993. Proton MR spectroscopic demonstration ofdifferences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. Neurology. 43(12):2484-90
Matthews PM, Ford B, Dandurand R, Eidelman D, O'Conner D, Sherwin A, Karpati G, Andermann F, Arnold DL. 1993.
Coenzyme Q10 with multiple vitamins is generally ineffective in mitochondrial disease. Neurology. 43(5):884-89
1992
Arnold D, Matthews PM, Francis GS, O’Connor J, Antel JS. 1992. Proton magnetic resonance spectroscopic imaging formetabolic characterisation of demyelinating plaques. Ann Neurol. 31(3):235-241
1991
Matthews PM, Allayer C, Tunbridge EA, Karpati G, Silver K, Carpenter S, Arnold DL. 1991. In vivo muscle magnetic
resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology 41(4):114-20
Matthews PM, Arnold DL, Francis G, Antel J. 1991. Proton magnetic resonance spectroscopy for metabolic
characterisation of plaques in multiple sclerosis. Neurology. 41(8):1251-56
Matthews PM, Berkoric S, Tamper D, Andermann F, Arnold DL. 1991. Magnetic resonance imaging shows specificabnormalities in the MELAS syndrome. Neurology. 41(7):1043-46
Matthews PM, Berkovic S, Shoubridge EA, Andermann F, Karpati G, Carpenter S, Arnold DL. 1991. In vivo magnetic
resonance spectroscopy of brain and muscle in a type of mitochondrial encephalopathy (MERRF). Ann Neurol. 29(4):43538
Karpati G, Arnold D, Matthews PM, Carpenter S, Andermann F, Shoubridge EA. 1991. Correlative multidisciplinary
approach to the study of mitochondrial encephalomyopathies. Rev Neurol (Paris) 147(6-7):455-61
1990
Matthews PM, Andermann F, Arnold DL. 1990. A proton magnetic resonance spectroscopy study of focal epilepsy inhumans. Neurology. 40(6):985-89
Arnold DL, Matthews PM, Francis G., Antel J. 1990. Proton magnetic resonance spectroscopy of human brain in vivo inthe evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med. 14(1):154-59
1989
Matthews PM, Shoubridge EA, Arnold DL. 1989. Brain phosphorus magnetic resonance spectroscopy in acute bacterial
meningitis. Arch Neurol. 46(9):994-96
Matthews PM, Evans A, Andermann F, Hakim A, Andermann E. 1989. Regional cerebral glucose metabolism differs in
the adult and the rigid juvenile forms of Huntington's disease. Ped Neurol 5(6):353-56
1986
Matthews PM, Taylor DL, Radda GK. 1986. Biochemical mechanisms of acute contractile failure in the hypoxic rat heart.
Cardiovasc Res. 20(1):13-19
Taylor DJ, Matthews PM, Radda GK. 1986. Myoglobin-dependent oxidative metabolism in the hypoxic rat heart. Respir
Physiol. 63(3):275-83
Taylor DJ, Arnold DA, Matthews PM, Gadian DG, Bore P, Styles P, Radda GK. 1986. Energetics of human muscle:
exercise induced ATP depletion. Magn Reson Med. 3(1):44-54
Matthews PM, Foxall DL, Shen L, Mansour TE. 1986. Nuclear magnetic resonance studies of carbohydrate metabolism
and substrate cycling in Fasciola hepatica. Molec Pharm. 29(1):65-73

Malloy CR, Matthews PM, Smith MB, Radda GK. 1986. Influence of propranolol on acidosis and high energy30
phosphates in ischaemic myocardium of the rabbit. Cardiovasc Res. 20(10):710-20
1985
31
Keogh JM, Matthews PM, Seymour AM, Radda G.K. 1985. A phosporus- P nuclear magnetic resonance study ofeffects of altered thyroid state on cardiac bioenergetics. Adv Myocardiol. 6:299-309
Matthews PM, Shen L, Foxall DL, Mansour TE. 1985.
hepatica. Biochim Biophys Acta. 845(2):178-88

31

P NMR studies of metabolite compartmentation in Fasciola

1984
Arnold DL, Matthews PM, Radda GK. 1984. Metabolic recovery after exercise and the assessment of mitochondrial
function in vivo in human skeletal muscle by means of 31P NMR. Magn Reson Med. 1(3):307-15
13

Shen L, Matthews PM, Foxall DL, Mansour TE. 1984. P NMR study of intact liver fluke Fasciola hepatica and its HCl04
extract. (Chinese) J Micro Radiofreq Spectro. 1:495-502
1982
Thulborn KR, Waterton JC, Matthews PM, Radda GK. 1982. Oxygenation dependence of the transverse relaxation timeof water protons in whole blood at high field. Biochim Biophys Acta. 714(2):265-270
31Matthews PM, Williams SR, Seymour AM, Schwartz A, Dube G, Gadian DG, Radda GK. 1982. A P NMR study of somemetabolic and functional effects of the in otropic agents epinephrine and ouabain, and the ionophore RO2-2985 (X537A)
in the isolated, perfused rat heart. Biochim Biophys Acta. 720(2):163-171
31

Matthews PM, Bland JL, Gadian DG, Radda GK. 1982. A P NMR saturation transfer study of the regulation of creatine
kinase in the rat heart. Biochim Biophys Acta. 721(3):312-320
1981
13
Bailey I, Gadian DG, Matthews PM, Radda GK. 1981. Studies of metabolism in the isolated, perfused rat heart using C
NMR. FEBS Lett. 123(2):315-318
Matthews PM, Bland JL, Gadian DG, Radda GK. 1981. The steady-state rate of ATP synthesis in the perfused rat heart
31
measured by P NMR saturation transfer. Biochim Biophys Res Comm. 103(3):1052-1059
Books
Matthews PM, Arnold DL. (1991) Diagnostic Tests in Neurology, New York: Churchill Livingstone
Hilton-Jones D, Taylor DJ, Squier MV, Matthews PM. (1995) Metabolic Myopathies, London: WB Saunders
Jezzard P, Matthews PM, Smith S. (eds.) (2001) Functional Magnetic Resonance Imaging: Methods for Neuroscience,
Oxford: Oxford University Press
Matthews PM, McQuain J. (2003) The Bard on the Brain: Understanding the Mind through the Art of Shakespeare andthe Science of Brain Imaging, New York and Washington: Dana Press[2004 IPPY Award Winner for Best Books of the Year (Psychology Category)]
Nalbantian, S, Matthews, PM, McClelland, J. (eds.) (2010) The Memory Process, Boston: MIT Press
Unreferreed Reviews, chapters in books and letters
Dube G, Gadian DG, Matthews PM, Radda GK, Seymour AM, Schwartz A, Williams SR. 1982. The relationship between
pressure development induced by inotropic agents and high-energy phosphate compounds in the Langendorff-perfused31
rat heart: A PNMR Study. In: Non-invasive Probes of Tissue Metabolism (ed. JS Cohen), John Wiley, New York, pp.
185-194
Matthews PM, Radda GK. 1997. Applications of nuclear magnetic resonance to the study of cardiac metabolism andpharmacology. In: Methods in Pharmacology: Myocardial Biology (Ed. A. Schwartz), Plenum Press, New York, pp.175-221
31

Keogh JM, Matthews PM, Seymour AM, Radda GK. 1985. A P NMR study of the effects of altered thyroid state on
cardiac bioenergetics. In: Advances in Myocardiology VI (Ed. N.Dhatta and D.J. Hearse), Plenum Press, New York,
pp.299-310
31

Malloy CR, Matthews PM, Smith MB, Radda GK. 1985. In vivo P NMR study of the regional metabolic response to
cardiac ischaemia. In: Advances in Myocardiology VI (Ed. N Dhatta and DJ Hearse), Plenum Press, New York, andpp.461-464

Matthews PM, Mansour TE. 1987. Applications of NMR to investigation of metabolism and pharmacology of31
parasites. In: Molecular Paradigms for Eradicating Helminthic Parasites (Ed. A.McInnes). UCLA Symposium in
Molecular and Cellular Biology. Alan R Liss, New York, Vol. 59.
Matthews PM, Andermann F, Arnold DL. 1991. Proton magnetic resonance spectroscopy study of chronic
encephalitis and epilepsy. In: Chronic Encephalitis and Epilepsy: Rasmussen’s syndrome. (Ed. F Andermann).
Butterworths, New York
Matthews PM, Arnold DL. 1990. Phosphorus magnetic resonance spectroscopy of brain in mitochondrial cytopathies(Letter). Ann Neurol 28:839-840
Matthews PM, Arnold DL. 1993. Coenzyme Q (Letter). Neurology 43:628
Arnold D, Matthews PM. 1996. Focal brain lesions in human subjects investigated using MRS. Ed. Grant DM and Harris
RK London, John Wiley & Sons. Encyclopaedia of NMR. 2083-90
Arnold DL, Matthews PM. 1996. Clinical applications of brain magnetic resonance spectroscopy. In Magnetic Resonance
Spectroscopy: Clinical Applications and Techniques (Eds. I.Young, C. Charles) Martin Dunitz, London
Matthews PM, Karpati, GK. 1996. Pattern of X-inactivation as a key determinant of the clinical-pathological phenotype ofDuchenne muscular dystrophy carriers. (Letter). Neurology 46:1189-90
Matthews PM. Mind's Valleys. 1997. Times Higher Education. Suppl. May 16, p.28
Arnold DL, Matthews PM, De Stefano N. 1997. MRI and Proton MRS in the Evaluation of Multiple Sclerosis. In: Magnetic
Resonance Spectroscopy and Imaging in Neurochemistry; Volume 8 of Advances in Neurochemistry, Plenum Press New
York
Matthews PM, Taivassalo T. 1997. Applications of Magnetic Resonance Spectroscopy to Diagnosis and Monitoring ofMitochondrial disease. Ital J Neurol Sci. 18:341-351
Arnold DL, Wolinsky JS, Matthews PM, Falini A. 1998. The use of brain magnetic resonance spectroscopy for theevaluation of the natural history of in MS. J Neurol Neurosurg Psych 64:S94-S101
Matthews PM, Lee M, Evangelou N. 1998. Is the normal appearing white matter so normal? Frontiers in Multiple
Sclerosis III (ed. H. Link, S. Fredrikson, Martin Dunitz) pp.91-100
Arnold DL, Matthews PM. 1999. Measures for quantification of axonal damage in vivo based on magnetic resonancespectroscopic imaging. In: Multiple Sclerosis Therapeutic”: ed. R Rudick, D Goodkin, Martin Dunitz, London pp.119-128
Arnold DL, Narayanan S, De Stefano N, Reddy H, Matthews PM. 1999. Magnetic resonance spectroscopy of multiple
sclerosis: imaging axonal damage. Advances in Multiple Sclerosis IV. Published in association with the American &European Committees for Treatment and Research in MS (ACTRIMS and ECTRIMS). Multiple Sclerosis Tissue
Destruction and Repair 8:77-89
Matthews PM. 1999. Axonal loss and demyelation in multiple sclerosis. Editorial Commentary. J Neurol Neurosurg
Psychiat 67:710-715
Arnold DL, De Stefano N, Narayanan S, Matthews PM. 2000. Axonal injury and disability in multiple sclerosis: Magnetic
Resonance Spectroscopy as a measure of dynamic pathological change in white matter. In: Magnetic Resonance
Spectroscopy in Multiple Sclerosis. Milan In press
Reddy H, Matthews PM. 2000. Functional Magnetic Resonance Imaging and Multiple Sclerosis: Cortical Reorganisation
and Recovery. In: Magnetic Resonance Spectroscopy in Multiple Sclerosis. Milan In press
Matthews PM. Stroke. 2002. Oxford Companion to the Body (ed. C. Blakemore et al.) Oxford University Press
Matthews PM. 1999. Distal myopathies: clinical and molecular diagnosis and classification. J Neurol Neurosurg Psychiat.
67:703-9
Matthews PM. 1999. The future of stroke imaging. (ed. Walter Holland) Stroke, the past, present and future. Chapter 17,
pages 75-80
DeStefano N, Narayanen S, Matthews PM, Mortilla M, Dotti MT, Federico A, Arnold DL 2000. Proton MR spectroscopy
to assess axonal damage in multiple sclerosis and other white matter disorders. J Neurovirol Suppl 2: S121- Review

Arnold DL, Matthews PM. 2000. Localisation and registration issues important for serial MRS studies of focal brain32
lesions. Methods in Biomedical Magnetic Resonance Spectroscopy of Multiple Sclerosis. John Wiley & Sons Ltd. 2: pp763-770
Reddy H, Lassonde M, Matthews PM. 2000. Functional MRI cerebral activation and deactivation during finger movement.
[Letter]. Neurology 55(8):1244
Arnold DL, De Stefano N, Matthews PM, Trapp BD. 2001. N-acetylaspartate: Usefulness as an indicator of viable
neuronal tissue. Ann Neurol 50(6): 823-5
Matthews PM, Fu S, Chen Y, Iverson S. 2002. Functional Magnetic Resonance Imaging: A promising tool for defining
the organization of Chinese language in the brain. In Cognitive Neuroscience Studies of the Chinese Language (Ed.
Henry SR, Kao CK, Leong and DG Gao). Hong Kong University Press
Arnold DL, Matthews PM. 2002. MRI in the diagnosis and management of MS. Neurology 58(8 Suppl 4):S23-31
Matthews PM. 2002. White matter changes and stroke risk. J Neurol Neurosurg Psych 72(5):564-565
Cifelli A, Matthews PM. 2002. Cerebral plasticity in multiple sclerosis: insights from fMRI. Mult Scler 8(3):193-9
Parry A, Matthews PM. 2002. Functional magnetic resonance imaging (fMRI): a “window” into the brain. Interdiscipl Sci
Rev 27(1):50-54
Matthews PM. 2004. Commentary on “Freud’s Theory of Mind and Functional Imaging Experiments” Neuropsychoanalysis. 6(1):145-149
Floyer-Lea A, Matthews PM. 2002. The clinical potential of MR at 3T: developing an integrated clinical-pathologicalview of brain injury. Clinical MRI/Developments in MR. 12(2):31-34
Arnold DL, Matthews PM. Measures to quantify axonal damage in vivo based on magnetic resonance spectroscopy.
ndChapter 10 in Multiple Sclerosis Therapeutics-2 Ed. (Eds. R. Rudick & D. Goodkin)
Matthews PM. Brain 2002. Book review: Neuroenergetics. Brain. Editorial commentary to Narayanan et al. 2001
Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol. 248(11):987
Heal R. and Matthews PM. 2002. Evidence of a cerebrocerebellar network: an fMRI study of functional integration
during visuospatiomotor sequence learning. Ann N Y Acad Sci 978:517-8
Zarei M, Johansen-Berg H, Matthews PM. 2003. Diffusion tensor imaging and tractography in clinical neurosciences.
Iran. J Radiol. 45-50
Wegner C, Matthews PM. 2003. A new view of the cortex, new insights into multiple sclerosis. Brain 126(Pt 8):17191721
Matthews PM. 2003. Functional Magnetic Resonance Imaging: Principles and Illustrative Applications for
Otolaryngology. In: Scott-Brown’s Otorhinolaryngology Textbook. In press.
Cifelli A, Arnold DL, Matthews PM, 2004. MRI visualisation of Multiple Sclerosis. In: Myelin Biology and its Disorders(Vol.2) (Ed. R.A. Lazzerini), Elsevier, Amsterdam, pp. 763-790
Wegner C, Smith S, Matthews PM. 2003. Measuring and interpreting white matter volume changes in multiple sclerosis.
In: Normal appearing white and grey matter damage in Multiple Sclerosis. (Ed. M Filippi, G Comi, M Rovaris). Springer,
2004
Parry AM, Clare S, Matthews PM. 2003. Rapid, whole brain T1 relaxation time measurements for the quantitative
definition of pathological changes in multiple sclerosis. In: Normal appearing white and grey matter damage in Multiple
Sclerosis. (Ed. M. Filippi, G. Comi M. Rovaris). Springer, 2004
Matthews PM. 2004. Editorial comment- Finding landmarks for understanding white matter Stroke. 35(1): 92-3
Matthews PM. 2005. Functional brain reorganization and recovery after injury to white matter. In Waxman, S. (Ed.)
Multiple Sclerosis as a Neuronal Disease. Elsevier Academic Press: Boston, pp.451-66
Voets NL, Matthews PM. 2005. Clinical applications of functional magnetic resonance imaging. Imaging Decisions MRI.
9(1):16-22

Caramanos Z, Matthews PM, Arnold DL. 2007. Axonal pathology in patients with multiple sclerosis: evidence from33
in vivo proton magnetic resonance spectroscopy. Multiple Sclerosis Therapeutics, 3rd Edition pp. 201-216.
Matthews PM. Pharmacological applications of fMRI. 2009. fMRI Techniques and Protocols. Springer- Verlag:
Heidelberg and New York, pp751-768
Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, Dixon IJ, Hallett WA, Whitcher B, Brown
AP, Zvartau-Hind M, Lotay N, Lai RY, Castiglia M, Jeter B, Matthews JC, Chen K, Bandy D, Reiman EM, Gold M,
Rabiner EA, Matthews PM. 2011. Validation and pilot application of [18F]FDG-PET in evaluation of a metabolic
therapy for Alzheimer’s disease. JW Ashford, A Rosen, M Adamson, P Bayley, O sabri, A Furst, SE Black, M Weiner(Ed.) Handbook of Imaging the Alzheimer Brain (Vol. 2). IOS Press: Amsterdam
Matthews PM. Pharmacological applications of fMRI. 2009. R Hill and H Rang (Ed.) Drug Discovery and Developmentnd(2 Edition). Elsevier: New York. In press
Panel report. Review of Research Using Non-Human Primates (The Bateson Report). BBSRC, MRC, NC3R,
Wellcome Trust: London. 2011